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ABSTRACT 
The main goal of this study is to seek the effects of some risk and prognostic factors contributing to sur-
vival of female invasive breast cancer in United States. The study presents the survival analysis for the 
adult female invasive breast cancer based on the datasets chosen from the Surveillance Epidemiology 
and End Results (SEER) program of National Cancer Institute (NCI). In this study, the Cox proportional 
hazard regression model and logistic regression model were employed for statistical analysis. The odds 
ratios (OR), hazard ratios (HR) and confidence interval (C.I.) were obtained for the risk and prognosis 
factors. The study results showed that some risk and prognosis factors, such as the demographic factors 
(race and age), social and family factor (marital status), biomedical factors (tumor size, disease stage, 
tumor markers and tumor cell differentiation level etc.) and type of treatment patients received had 
significant effects on survival of the female invasive breast cancer patients.  
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1 INTRODUCTION  
1.1 Purpose of study 
Breast cancer is the second most common cancer among American women (CDC 2007). In re-
cent years, more than 200,000 new cases of breast cancer were diagnosed in the United States in each 
year.  Almost 40,000 women may die due to breast cancer in 2012. Only lung cancer accounts for more 
cancer deaths in women (American Cancer Society 2011, SEER 2011).   
Age and Race are factors commonly considered to have effect on prognosis and survival of 
breast cancer. The incidence and death rate of breast cancer significantly increases with age (CDC  
2007). Over 90% of new breast cancer cases and almost 100% deaths occur in American women over 40 
year-old age. Almost 80% of invasive breast cancer cases occur in 50 year- old or above female breast 
cancer patients. Among adult American females, 20-24 year-old females have the lowest breast cancer 
incidence rate; women over 65 year-old have the highest incidence rate. The median breast cancer di-
agnosis age is 61 year-old (American Cancer Society 2011). Secondly, in non-Hispanic white females, the 
breast cancer incidence rate was reported higher than African American women and other racial and 
ethnic populations (American Cancer Society 2011). However, some previous publications reported that 
African American breast cancer patients have a lower survival rate compared to White female patients. 
According to SEER Cancer Statistics Review, in the United States, among all race/ethnicity groups, the 
females’ lifetime risk of dying from breast cancer from year 2006 to year 2008 for Whites was 2.76 (95% 
C.I. 2.74-2.77), for African American was 3.25 (95% C.I. 3.20-3.30), for Asian/Pacific Islanders was 1.69 
(95% C.I. 1.59-1.81), for Hispanics was 2.03 (95% C.I. 1.96-2.11) and for American Indian/Alaska Natives 
was 1.82 (95% C.I. 1.58-2.13). Moreover, the female age-adjusted death rate for breast cancer from year 
2004 to year 2008 for Whites was 22.8/100,000, for African Americans was 32.0/100,000, for 
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Asian/Pacific Islanders was 12.2/100,000, for Hispanics was 17.2/100,000,  and for American Indi-
an/Alaska Natives was 14.3/100,000 (Bassett 1986, American Cancer Society 2011). 
In addition, tumor size, tumor extension and tumor histopathologic characteristics, such as can-
cer cell differentiation degree, tumor markers, are highly associated with survival of cancer patients and 
are considered as important prognosis factors (Elston and Ellis 1991).   The extension of the disease, 
known as the extent or spread of the malignant tumor when it is diagnosed will significantly affect the 
seriousness of invasive breast cancer (SEER 2011). Some other factors, such as clinical treatments the 
patients received, also contribute to the prognosis and survival of breast cancer (Early breast cancer 
trialists’ collaborative group 2005).  
The purpose of this study is to explore the effects of risk and prognosis factors on survival or 
death of the adult female invasive breast cancer patients in the United States. To achieve this purpose, 
the Cox proportional hazard regression models and logistic regression models were constructed for the 
Surveillance Epidemiology and End Results data (SEER) to calculate the hazard ratios (HR), odds ratios 
(OR) and confidence interval (CI) for risk and prognosis factors.  
1.2 Expected results 
The expected results: many risk factors and prognosis factors, such as demographic factors (age 
at diagnosis and race/ethnicity), social factors (marital status), and biomedical factors (tumor 
histopathologic characteristics) have significant effects on survival of female breast cancer patients. The 
treatments patients received are also expected to prolong the survival times. This will provide important 
information about early detection, screening and treatment of the invasive breast cancer and help to 
improve the survival rate of American women with breast cancer. 
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2 STUDY SCENARIO 
2.1 Data source 
The data used in this study were obtained (in TXT format) from the Surveillance Epidemiology 
and End Results (SEER) program of National Cancer Institute (NCI), a premier source for cancer statistics. 
The original data sets downloaded from the SEER’s website contain cases from 12 geographic registry 
areas in the United States diagnosed from year 1973 to 2008.  The adult female (20 years old and above) 
primary invasive breast cancer patients diagnosed from year 1990 to 2002 with active follow-up were 
selected for analyzing the effects of demographic factors, social/family factor and biomedical prognosis 
factors on breast cancer survival.  
2.2 Study design  
In this study, the dataset including the adult female patients with primary invasive breast cancer 
diagnosed from 1990 to 2002 was used to analyze the effects of demographic factors (age and 
race/ethnicity), social factor (marital status), biomedical and histopathologic factors (tumor cell differen-
tiation grade, tumor size, tumor extension, lymph node metastasis and treatments patients received 
etc.) on survival or death among female primary invasive breast cancer patients. The dataset in this 
study contains total 370133 female breast cancer patients in 12 geographic areas of the United States 
diagnosed from year 1990 to year 2002, and at the end of the year 2008, 221094 (59.73%) subjects were 
still alive at the cut-off point, 67740 (18.30%) subjects were dead due to breast cancer and other 81299 
(21.96%) participants were dead due to other diseases during the time period.  Logistic regression mod-
els and Cox proportional hazard regression models were constructed to analyze the effect of all risk and 
prognosis factors and calculate the odds ratio and hazard ratio. In this study, the SAS 9.2 statistical soft-
ware procedures (logistic procedure, lifetest procedure and phreg procedure etc.) were used to do data 
analysis. 
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2.3       Risk and prognostic factors for survival of female breast cancer patients  
The survival and prognosis of breast cancer is affected by many factors, and those factors that 
are associated with prognosis of disease are considered as risk and prognosis factors.  Risk and prognosis 
factors in this study include demographic factors, social factor and prognosis factors include biomedical 
or histopathologic factors.  
Demographic factors of participants include age and race/ethnicity.  Age was considered as the 
most important risk factor for female breast cancer patients (American Cancer Society 2011). The classi-
fication of those ages at diagnosis of the patients in this study was expanded to 4 groups: 20-39 years 
old, 40 to 49 years old, 50 to 64 years old and 65 years old and above. All the patients in this study were 
classified into 6 race/ethnicity groups: non-Hispanic Whites, African American, Hispanic, Asian and Pacif-
ic Islander, American Indian/Alaskan Native and other races.  
Patients’ marital status was considered as a social relations factor. In this study, patients’ marital 
status is determined using responses to the study program, “now married”, “widowed, divorced or sep-
arated”, or “never married”.   
Biomedical factors include tumor size, tumor markers, tumor cell differentiation grade, lymph 
node examination result and tumor extension. Tumor size at the time of diagnosis was classified into 5 
classes: tumor less than 2cm, 2-5cm, over 5cm, unclear cases and Paget’s disease of nipple with no de-
monstrable tumor; tumor cell differentiation grade includes five groups: well differentiated, moderately 
differentiated, poorly differentiated, undifferentiated and unknown cases; local lymphatic metastasis 
includes three categories: negative examination result , positive result and unclear cases; tumor markers    
(include the estrogen receptor assay, ERA and progesterone receptor assay, PRA)  were classified into  
positive marker group, negative marker group, borderline group and unclear group, respectively; the 
tumor extension was classified into four groups: localized, regional, distant and extension unknown. In 
addition, the treatment methods: surgery and radiotherapy were also considered as prognosis factors 
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for survival and prognosis of breast cancer patients. Treatments were categorized into the following 
groups: no treatment, treatment and treatment unknown. 
2.4         Dependent variables 
In survival analysis of the SEER data, the survival time (months of survival from baseline to death 
or to December 31, 2008) and survival status (alive or censoring and dead) were used as the dependent 
variables. In logistical model, the categorical variable, survival status (dead and alive or censoring) was 
set to be the outcome variable.  
2.5         Statistical analysis method 
At the beginning of the study, the differences in frequency and percentage of demographic fac-
tors, social factors, biomedical and histological factors were examined by using the SAS freq procedure. 
A chi-square analysis was also used for the difference of survival status among age groups and 
race/ethnicity groups. The significance of difference of the incidence rates among all age groups was 
tested as well. 
In survival analysis study, the SAS lifetest procedure can be used to calculate the nonparametric 
estimates of the survival functions, and it also can be used to do comparison among survival curves and 
the rank tests computation for association of the event time with covariates (SAS Institute Inc. 2012).  In 
this study, the lifetest procedure was used to check the effect of demographic factors, social factors, 
biomedical and histological factors on survival and hazard functions and test the Cox proportionality as-
sumption via visual examinations of survival curves and “log-log” plots curves.  In addition, the Cox’s 
proportional hazards model was constructed for this complex study dataset. If t is the observed time of 
event occurrence, T represent the random variable of survival time, which is defined on the domain t ∈   
[0,∞). Then S(t) is the survival function, S(t) = p(T > t), i.e. the probability of surviving at least to time t. 
As a probability, it has range S(t)∈  [0, 1]. S(t) = 1 - F(t) =∫t
∞f(τ)dτ. The hazard function represents the 
concept of the risk of dying at the time t, given the subject having survived to time t, which is defined as  
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h(t) = lim⊿  t→0 
        ⊿      
⊿ 
            . 
In the Cox’s proportional hazards model, we can start with a baseline hazard function and set it 
as h0(t). We can model the effect of some covariates on the hazard function which is given by 
h(t|Z) = ho(t)exp(β
TZ) 
when h0(t) is the unspecified baseline hazard function. If h(t|Z) denotes the hazard rate at time t for an 
individual with risk vector Z . The Cox model is 
h(t|Z)= ho(t)c(β
tZ) (Cox, 1972), 
with the parameter vector β=(β1, β2, β3, … …, βi)
t  (Cox, 1972). In Cox proportional hazard model, if we 
compare two subjects with covariate values Z and Z*, the ratio of the two hazard rates is given by  
      
       
 
                 
 
   
               
  
 
   
=exp[           
   
 
   , 
which is the relative risk of one subject with the risk factor Z having an event compared to a subject with 
risk factor Z* (Klein and Moeschberger 2003). The SAS phreg procedure was used to construct the model 
and the hazard ratio and its confidence interval (CI) for each factor were also obtained through this pro-
cedure (SAS Institute Inc. 2012).  
 In addition, a multivariate logistic regression model was used to check the effect of the risk and 
prognosis factors on breast cancer 5-year relative survival and calculate the odds ratio (OR) and its con-
fidence interval (CI) for each factor. The logistic regression model can be used to investigate the rela-
tionship between a discrete response variable and a series of explanatory variables. The SAS logistic pro-
cedure can be used to fit a linear logistic regression model for a discrete survey response variable by 
maximum likelihood method (SAS Institute Inc. 2012). 
 In this study, the SAS software (version 9.2, SAS Institute, Cary, NC) was used in data analysis 
and p-value less than significance level 0.05 was considered to be statistical significant. 
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3 RESULTS 
3.1 Descriptive statistical analysis 
In this section, the differences in frequency and percentage of demographic factors, social factors, 
biomedical and histological factors were examined by using the SAS freq procedure (SAS 9.2, SAS Insti-
tute Inc.), and also a chi-square analysis was used for the difference of survival status among age groups, 
race/ethnicity groups and treatments groups. The tables in this thesis were created using Word, Excel 
and SAS ODS (Output Delivering System). 
3.1.1 Demographic characteristics: age and race/ethnicity 
Table 1. Frequency and percentage of participants in different race/ethnicity group 
Race Frequency Percentage 
Non-Hispanic White 287818 77.76% 
African American  31144 8.41% 
Hispanic 26589 7.18% 
Asian 22832 6.17% 
American Native 1601 0.43% 
Other 149 0.04% 
Total 370133 100.00% 
 
Total 370133 adult female patients with primary invasive breast cancer diagnosed from 1990 to 
2002 in SEER data resource were selected in this study. 287818 (77.76%) patients were non-Hispanic 
Whites; 31144 (8.41%) were African-American females; 26589 (7.18%) were Hispanic females; 22832 
(6.17%) were Asians and 1601 cases (0.43%) were American Indians/Alaska Natives. Only 173 (0.04%) 
cases were other races/ethnics. 
In this study, the subjects were separated into 4 different age groups (Table 2): 20-39 years old 
(21608, 5.84%) and 40 to 49 years old (64122, 17.32%), 50 to 64 years old (119346, 32.24%) and 65-year 
old and above (165057, 44.59%). The mean and median age at diagnosis were 61.8 year-old and 62 year-
old, respectively (SAS means Procedure, SAS institute inc. 2012).  
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Table 2. Frequency and percentage of participants in different age groups 
Age Frequency percentage 
20-39 21608 5.84% 
40-49 64122 17.32% 
50-64 119346 32.24% 
65 and above 165057 44.59% 
Total 370133 100% 
 
Table 3. Age at diagnosis and the survival/death status two-way table  
Frequency 
Percentage 
Row Pct 
Column Pct 
Death due to breast 
cancer 
Death due to other 
reasons 
Alive Total 
20-39 
5955 
1.61 
27.56 
8.79 
 
770 
0.21 
3.56 
0.95 
 
14883 
4.02 
68.88 
6.73 
 
21608 
5.84 
  
  
 
40 to 49 
12333 
3.33 
19.23 
18.21 
 
2911 
0.79 
4.54 
3.58 
 
48878 
13.21 
76.23 
22.11 
 
64122 
17.32 
  
  
 
50 to 64 
20673 
5.59 
17.32 
30.52 
 
11955 
3.23 
10.02 
14.70 
 
86718 
23.43 
72.66 
39.22 
 
119346 
32.24 
  
  
 
65 and above 
28779 
7.78 
17.44 
42.48 
 
65663 
17.74 
39.78 
80.77 
 
70615 
19.08 
42.78 
31.94 
 
165057 
44.59 
  
  
 
Total 
67740 
18.30 
 
81299 
21.96 
 
221094 
59.73 
 
370133 
100.00 
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From table 2 we found that the proportion of 20-39 year-old patients in this study was only 
5.84%, and among all the other older age groups, the percentage increased with age. The difference of 
percentages among all age groups was significant (P<0.0001).  This indicates that breast cancer inci-
dence rate increases with age (American Cancer Society 2011).  
When age at diagnosis increased, the overall death rate due to all the reasons also increased 
(Table 3). The “50 to 64 year-old” and the “65 year-old and above” age groups had the higher death rate 
among all age groups (P<0.0001).  However, in this study, the 20-39 years old age group had a relatively 
higher breast cancer specific death rate: 27.56% of patients in this age group died of breast cancer. In 
the 40-49 year-old age group, the breast cancer specific death rate was 19.23%, and in the 50-64 year-
old and 65 year-old and above age groups, the breast cancer specific mortalities were only 17.32% and 
17.44%, respectively. 
Some previous studies reported that African American breast cancer patients had a lower sur-
vival rate compared to White female patients due to the lower social-economical status (Bassett, 1986; 
American Cancer Society 2011). From table 4 below, we also can found that African American patients 
had highest breast cancer specific death rate (29.32%) and overall lowest long-term survival rate 
(50.28%) among all races/ethnics (P<0.0001).  
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Table 4. Race/ethnicity and survival/death status two-way table 
Frequency 
Percentage 
Row Pct 
Column Pct 
Death due to breast 
cancer 
Death due to other 
reasons 
Alive Total 
Non-Hispanic 
Whites 
49031 
13.25 
17.04 
72.38 
 
67482 
18.23 
23.45 
83.00 
 
171305 
46.28 
59.52 
77.48 
 
287818 
77.76 
  
  
 
African American  
9130 
2.47 
29.32 
13.48 
 
6355 
1.72 
20.41 
7.82 
 
15659 
4.23 
50.28 
7.08 
 
31144 
8.41 
  
  
 
Hispanic 5630 
1.52 
21.17 
8.31 
 
4132 
1.12 
15.54 
5.08 
 
16827 
4.55 
63.29 
7.61 
 
26589 
7.18 
  
  
 
Asian 
3559 
0.96 
15.59 
5.25 
 
3026 
0.82 
13.25 
3.72 
 
16247 
4.39 
71.16 
7.35 
 
22832 
6.17 
  
  
 
Native 383 
0.10 
23.92 
0.57 
292 
0.79 
18.24 
0.36 
926 
0.25 
57.84 
0.42 
1601 
0.43 
Other 7 
0.00 
4.70 
0.01 
12 
0.00 
8.05 
0.01 
130 
0.04 
87.25 
0.06 
149 
0.04 
Total 
67740 
18.30 
 
81299 
21.96 
 
221094 
59.73 
 
370133 
100.00 
 
Note: Pct-percentage 
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3.1.2 Social/Family factor: marital status 
Table 5. Marital status of participants  
Marital Status Frequency Percentage 
Married 200286     54.11% 
Ever Married 114687    30.99% 
Single 42129    11.38% 
Unknown 13031 3.52% 
Total 370133 100.00% 
 
Table 6. Marital status by different race/ethnicity 
Frequency 
Percentage 
Row Pct 
Column Pct 
Married Ever married Single Unknown Total 
Non-Hispanic 
Whites 
158945 
42.94 
55.22 
79.36 
 
90979 
24.58 
31.61 
79.33 
 
27934 
7.55 
9.71 
66.31 
 
9960 
2.69 
3.46 
76.43 
287818 
77.76 
  
  
 
African Ameri-
can  
11117 
3.00 
35.70 
5.55 
 
11433 
3.09 
36.71 
9.97 
 
7176 
1.94 
23.04 
17.03 
 
1418 
0.38 
4.55 
10.88 
31144 
8.41 
  
  
 
Hispanic 
14595 
3.94 
54.89 
7.29 
 
7037 
1.90 
26.47 
6.14 
 
4044 
1.09 
15.21 
9.60 
 
913 
0.25 
3.43 
7.01 
26589 
7.18 
  
  
 
Asian 
14799 
4.00 
64.82 
7.39 
 
4828 
1.30 
21.15 
4.21 
 
2735 
0.74 
11.98 
6.49 
 
470 
0.13 
2.06 
3.61 
22832 
6.17 
  
  
 
Native 743 
0.20 
46.41 
385 
0.10 
24.05 
214 
0.06 
13.37 
259 
0.07 
16.18 
1601 
0.43 
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As shown in table 5, among total 370133 patients in this study, there were 200286 (54.11%) 
married participants; 42129 (11.38%) participants had never married; 114687 (30.99%) participants 
were widowed, divorced or separated and in this study, they were defined as ever married. The marital 
status of other 13031 (3.52%) patients was unclear. 
From Table 5 and 6 we found that African American females relatively had a significantly higher 
rate of single (23.04%) or currently single (ever married) ship (36.71%), and lower marriage rate 
(35.70%) compared with other races/ethnicities (P<0.0001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
0.37 0.34 0.51 1.99 
Other 87 
0.02 
58.39 
0.04 
25 
0.01 
16.78 
0.02 
26 
0.01 
17.45 
0.06 
11 
0.00 
7.38 
0.08 
149 
0.04 
Total 
200286 
54.11 
 
114687 
30.99 
 
42129 
11.38 
 
13031 
3.52 
370133 
100.00 
 
13 
 
3.1.3 Biomedical and pathological factors 
Table 7. Tumor cell differentiation grade  
Tumor Cell Differentiation Grade Frequency Percentage 
well differentiated 55510     15.00% 
Moderately differentiated 125402     33.88% 
Poorly differentiated 110689     29.91% 
Undifferentiated 8459      2.29% 
Unknown 70073     18.93% 
Total 370133 100.00% 
 
From table 7, we found that among all the invasive breast cancer cases in this study, 55510 
(15.00%) subjects were tumor cell well differentiated cases; 125402 (33.88%) were moderately differen-
tiated cases; 110689 (29.91%) were poorly differentiated, and 8459 (2.29%) cases were the rare undif-
ferentiated grade; other 70073 (18.93%) were unknown cases. 
 
Table 8. Tumor size  
Tumor Size Frequency Percentage 
2cm or less in diameter 217061     58.64% 
Paget’s disease 138 0.04% 
2-5cm in diameter 98375     26.58% 
Over 5cm in diameter 24665      6.66% 
Unknown 29894      8.08% 
Total 370133 100.00% 
 
Table 9. Lymph node examination result 
Lymph Node Examination Frequency Percentage 
Negative 193011     52.15% 
Positive 111855     30.22% 
Unknown 65267     17.63% 
Total 370133 100.00% 
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Table 10. Tumor extension 
Tumor Extension Frequency Percentage 
Localized 319500     86.32% 
Regional 19175     5.18% 
Distant 20464     5.53% 
Unknown 10994      2.97% 
Total 370133 100.00% 
 
Table 8 and 9 showed that in more than half cases (58.64%) the patients’ tumor sizes at the di-
agnosis were less than 2cm, and 85.22% of tumors were less than 5cm. There were 193011 (52.15%) 
patients had no regional lymph node metastasis at the time of diagnosis while 111855 (30.22%) patients 
had nodal involvement. Other 65267 (17.63%) cases did not have clear lymph node metastasis infor-
mation. A small size tumor without lymph node metastasis indicates an early disease stage and usually 
has a better prognosis and survival chance (American Cancer Society 2011).  
Invasive breast cancer extension was divided into three different histological stages in this 
study. The Localized extension indicates the tumor is confined entirely within the original organ; Region-
al extension indicates the tumor has extended into the surrounding organs or tissues and/or into the 
regional lymph nodes; the distant extension stage indicates the tumor has extended into the remote 
organ(s) with or without the lymph nodes metastasis (SEER 2011).  Table 10 indicated that the majority 
of participants in this study (319500, 86.32%) was in the localized extension stage; 19175 (5.18%) cases 
were in the regional stage; 20464 (5.53%) patients were in the relative later stage, the distant stage; and 
other cases were unclear (10994, 2.97%).  The long-term survival of breast cancer patients is highly af-
fected by the disease extension stage (Farley and Flannery 1989, SEER 2011).  Tumor size less than 2cm 
in diameter, lymph node negative status, tumor markers positive status, localized tumor and local ex-
tended tumor are considered as low-risk tumor characteristics with relative better prognosis and surviv-
al chance (Anderson and Jatoi et al. 2005). Table 11 indicated that a well differentiated tumor is usually 
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associates with an earlier extension stage (P<0.0001). For example, 95.89% well differentiated tumor 
were found without regional or distant extension. However, a decline of 12% was observed in the poorly 
differentiated tumor group. 
Table 11. Tumor cell differentiation grade and Tumor extension two-way table 
Tumor cell differentiation grade and Tumor extension two-way table 
Frequency 
Percentage 
Row Pct 
Column Pct 
Localized Regional Distant Unclear Total 
Well differentiated 
53226
 
14.38 
95.89 
16.66 
 
1227
 
0.33 
2.21 
6.40 
 
596
 
0.16 
1.07 
2.91 
 
461
 
0.12 
0.83 
4.19 
 
      55510 
 
15.00 
Moderately differentiated 
114107 
30.83 
90.99 
35.71 
 
5898 
1.59 
4.70 
30.76 
 
4011 
1.08 
3.20 
19.60 
 
1386 
0.37 
1.11 
12.61 
 
125402 
33.88 
Poorly differentiated 
92603 
25.02 
83.66 
28.98
 
 
7881 
2.13 
7.12 
41.10
 
 
8265 
2.23 
7.47 
40.39
 
 
1940 
0.52 
1.75 
17.65
 
 
110689 
29.91 
 
Undifferentiated 
7078 
1.91 
83.67 
2.22 
 
549 
0.15 
6.49 
2.86 
 
662 
0.18 
7.83 
3.23 
 
170 
0.05 
2.01 
1.55 
 
8459 
2.29 
 
Unknown 52486 
 
14.18 
 
74.90 
 
3620 
 
0.98 
 
5.17 
 
6930 
 
1.87 
 
9.89 
 
7037 
 
1.90 
 
10.04 
 
70073 
 
18.93 
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              16.43 18.88 33.86 64.01 
 
Table 12. Tumor marker ERA 
Tumor Marker ERA Frequency Percentage 
positive               225625 60.96% 
negative                66030 17.84% 
Borderline 1835      0.50% 
unknown                         76643 20.71% 
Total 370133 100.00% 
 
Table 13. Tumor marker PRA 
Tumor Marker PRA Frequency Percentage 
positive               188293     50.87% 
negative                94573     25.55% 
Borderline 2651     0.72% 
unknown                         84616     22.86% 
Total 370133 100.00% 
 
 Table 12 and table 13 showed the tumor markers examination result. ERA (estrogen receptor 
assay) and PRA (progesterone receptor assay) are two different tumor markers. More than 60% of pa-
tients had a positive ERA examination result and more than half of the patients (50.87%, table 13) had a 
positive PRA examination result. Positive expressions of tumor markers are associated with a relative 
better prognosis and also a higher survival chance (Anderson and Jatoi et al. 2005). 
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3.1.4  Clinical treatment factors: surgery and/or radiotherapy  
Table 14. Surgery treatment 
Surgery Treatment  Frequency Percentage 
Non-Surgery 21225      5.73% 
Surgery  348313    94.10% 
Unknown 595     0.16% 
Total 370133 100.00% 
 
Table 15. Radiation treatment 
Radiation Treatment  Frequency Percentage 
Non-Radiation 204600     55.28% 
Radiation  154698     41.80% 
Unknown 10835      2.93% 
Total 370133 100.00% 
    
In breast cancer, local treatment can significantly affect the risk of local or regional recurrence 
and long-term survival rate (Early Breast Cancer Trialists’ Collaborative Group 2005).  In this study, the 
effects of surgery and/or radiotherapy treatments the patients received were also considered as im-
portant prognosis factors. From table 14, 15 and 16, we found that more than 90% of the patients re-
ceived surgery treatment. However, only 154698 (41.8%) patients received the radiotherapy. 150332 
(40.62%) participants received both surgery treatment and radiotherapy treatment.  
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Table 16. Summary of the treatments  
Surgery and Radiotherapy Two-Way Table 
  no radiation radiation unknown Total 
no surgery 
16345 
4.42 
77.01 
7.99 
 
4337 
1.17 
20.43 
2.80 
 
543 
0.15 
2.56 
5.01 
 
21225 
5.73 
  
  
 
surgery 
187973 
50.79 
53.97 
91.87 
 
150332 
40.62 
43.16 
97.18 
 
10008 
2.70 
2.87 
92.37 
 
348313 
94.10 
  
  
 
unknown 282 
0.08 
47.39 
0.14 
 
29 
0.01 
4.87 
0.02 
 
284 
0.08 
47.73 
2.62 
 
595 
0.16 
  
  
 
Total 
204600 
55.28 
 
154698 
41.80 
 
10835 
2.93 
 
370133 
100.00 
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3.2 Survival analysis 
 
3.2.1 The effect of demographic factors on survival and hazard function 
In this part, the effects of all risk and prognosis factors on breast cancer survival and hazard func-
tions were examined by using SAS lifetest procedure. 
Figure 3.1 showed the effect of age at diagnosis on overall survival distribution function and haz-
ard function. The age group “65 and above” had the worst survival function and the highest hazard 
probability (P<0.0001). In addition, compared to other age groups, the overall survival probability of the 
“65 and above” age group decreased faster over time while all other survival curves showed a slow de-
creasing pattern.  The “40-49” year-old age group had the highest overall survival probability and the 
lowest hazard probability among all age groups.  However, although the “20-39” year-old age group had 
the minimum number of patients in this study, the overall survival probability of this group was only 
higher than the “65 and above” age group, but lower than the “40-49” year-old group and the “50-64” 
year-old group.  Figure 3.2 showed the effect of age at diagnosis on breast cancer specific survival distri-
bution function and hazard function. The age group of “20-39” had the worst survival function and the 
highest hazard probability (P<0.0001) compared to other age groups.   This is probably because the 
“high-risk” breast cancers (early age at onset, larger tumor size, axillary lymph node metastasis, worse 
histologic differentiation and negative tumor markers expression etc.) have more occurrences among 
the younger patients (Anderson and Jatoi 2005, Albain and Allred et al. 1994, Diab  and Elledge et al. 
2000). The breast cancer specific hazard curve of the “65 and above” group showed a slow decreasing 
pattern. For other age groups, the peaks of the breast cancer specific hazard curves all appeared around 
20-25 months after diagnosis and then slowly declined. As indicated by Jatoi and Tsimelzon, the highest 
risk of breast cancer death occurs around 2-3 years after the diagnosis (Jatoi and Tsimelon et al. 2005).  
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Figure 3.3 showed that the African American female patients had the worst breast cancer specific 
survival chance and the highest hazard rate comparing to non-Hispanic Whites, Asians and Hispanics. At 
the beginning, the African American group had a higher hazard rate and the peak was shown around 20 
months and then slowly decreased with time. Non-Hispanic Whites and Asians had better survival prob-
ability and the survival curves had a relative flat pattern.  However, the hazard rate curves of American 
Indian/Alaska Native and other races were unstable due to the relatively small sizes during a long-term 
follow-up time period. 
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Figure 3.1 The effect of age at diagnosis on overall survival and hazard function 
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Figure 3.2 The effect of age at diagnosis on breast cancer specific survival and hazard function 
 
 
 
 
 
23 
 
Figure 3.3 The effect of race/ethnicity factor on survival and hazard function 
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3.2.2 The effect of social factor on survival and hazard function 
Figure 3.4 showed that married people had the relative better survival ability among married, ever 
married and single (never married) groups (P<0.0001). There was no significant difference of survival or 
hazard function between the single group and the ever married group.  
Figure 3.4 The effect of marital status on survival and hazard function 
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3.2.3 The effect of biomedical prognosis factors on survival and hazard function 
Figure 3.5 The effect of cell differentiation grade on survival and hazard function 
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Tumor cell differentiation grade had significant effect on survival and hazard functions 
(P<0.0001).  Figure 3.5 showed that “well differentiated” group had the best survival probability; “poorly 
differentiated” and “undifferentiated” groups had lower survival probability. The peaks of hazard rate of 
both poorly differentiated and undifferentiated groups were shown around 20 months after diagnosis.  
However, the well differentiated group and the moderately differentiated groups had the flat pattern, 
and the well differentiated group had the lowest hazard rate. 
Figure 3.6 showed that tumor size is an important prognosis factor and had significant effect on 
female breast cancer survival (P<0.0001).   Tumor size less than 2cm and Paget’s disease cases had the 
best survival ability and the lowest hazard rate with relatively flat patterns as shown on figure 3.6. Tu-
mor size over 5cm patients had the highest hazard rate during all the follow-up time period and the 
peak appeared around 20 months after diagnosis.  
Figure 3.7 demonstrated the negative lymph node status (without regional lymph node metas-
tasis) had relatively better survival chance and the lowest hazard rate compared to the positive lymph 
node group (P<0.0001). The hazard rate of positive lymph node groups reached the peak after 20 
months and then decreased slowly.  
The hazard function for distant extension cases had the highest hazard rate in most time of fol-
low-up period. The localized extension group had the best survival ability and lowest hazard rate with a 
flat pattern curve (P<0.0001, figure 3.8). Figure 3.9 showed that patients with positive tumor maker ex-
pression had a better survival chance. 
Figures 3.6 to 3.9 indicated that all the histological and pathological factors had significant effect 
on both survival ability and hazard rate.  The lifetest procedure results showed that smaller tumor size, 
well differentiated tumor, positive tumor markers (figure 3.9), negative lymph node metastasis and early 
histological (localized tumor) disease stage had better survival ability. The “high-risk” tumors, such as 
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tumors with larger size, positive lymph node, negative tumor markers expression, poorly differentiated 
or undifferentiated tumors, regional or distant extension had lower survival probability. 
Figure 3.6 The effect of tumor size on survival and hazard function 
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Figure 3.7 The effect of lymph node metastasis on survival and hazard function 
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Figure 3.8 The effect of tumor extension on survival and hazard function 
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Figure 3.9 The effect of tumor markers on survival and hazard function 
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 3.2.4 The effect of treatments on survival function and hazard function 
Figure 3.10 The effect of surgery treatment on survival and hazard function 
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Figure 3.11 The effect of radiation treatment on survival and hazard function 
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Figure 3.12 The effect of treatments on survival function 
 
 
 
Figures 3.10 and 3.11 showed that both surgery and radiation treatments significantly improved 
the chance of surviving (P<0.0001). The hazard curve of the surgery group maintained a low and flat pat-
tern. However, hazard rate of the non-surgery group was very high at the beginning and dropped fast, 
after 15 months, the hazard curve maintained a slow deceasing pattern (table 3.10).  The radiotherapy 
group maintained the lowest hazard rate, the peak of the hazard curve appeared around 25 months and 
then the hazard rate slowly decreased (table 3.11). The patients received both surgery and radiation 
treatments had the best survival ability compared to those who only received radiotherapy or did not 
received any surgical or radiation treatment (figure 3.12, P<0.0001), suggesting that the treatments pa-
tients received are an important prognosis factor that can improve the survival chance of breast cancer 
patients. 
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3.3 Cox proportional hazard model and hazard ratio 
In this study, all the variables:  demographic variables (age race/ethic), social variable (marital 
status), histopathologic variables (tumor cell differentiation grade, tumor size, lymph node or distant 
organ metastasis and disease stage) and clinical treatments can be used as covariates to explain the re-
sponse variable.  Cox proportional hazard regression is a powerful method to examine the effect of vari-
ables by controlling other covariates in a complex dataset (SAS Institute Inc. 2012).  In this section, the 
Cox proportional hazard model was employed to check the effect of all risk and prognosis factors on dis-
ease specific and overall survival of invasive breast cancer patients and to calculate the hazard ratios of 
all the factors. First, a reference category in each factor was chosen and compared to the other levels in 
the same factor.   The reference set of covariates contained non-Hispanic White, 20-39 year-old, mar-
ried, tumor cell well differentiated, tumor size 2cm or less, localized extension, negative lymph node 
metastasis, positive tumor makers, surgery treatment and radiotherapy. Tables 17, 18 and 19 showed 
the obtained relative hazard ratio among the categories for all the factors.  
We can found that African Americans had relatively higher hazard ratio compared  to Whites 
and other race/ethnicity groups on both breast cancer specific survival and overall survival, which were 
1.352 and 1.235 respectively (P<0.0001, table 17).  The 20-39 year-old age group had the highest mortal-
ity risk on breast cancer specific survival (P<0.0001). The 65 and above age group had the lowest survival 
chance on overall survival (3.965, P<0.0001). Compared to married people, both single and currently 
single patients had significantly higher death hazard on breast cancer specific and overall survival 
(P<0.0001).  For example, for breast cancer specific survival, compared to married people, the hazard 
ratio of single patients was 1.208 (P<0.0001); for overall survival, the hazard ratio was 1.405 (P<0.0001). 
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Table 17. The effect of age race/ethnicity and marital status on hazard ratio  
 Breast cancer specific survival Overall survival 
Factors Hazard Ratio  95% C.I. P-value Hazard Ratio  95% C.I. P-value 
age       
20-39 (reference) 1.000   1.000   
40-49  0.751        0.726   0.776 <.0001 0.982 0.948   1.107 0.3042 
50-64 0.709        0.682   0.737 <.0001 1.456 1.392   1.523 <.0001 
65 and above 0.786 0.748   0.826 <.0001 3.965 3.740   4.204 <.0001 
Race/ethnicity       
White (reference) 1.000   1.000   
Asian  0.907       0.835   0.984 0.0186 0.814 0.764   0.847 <.0001 
Black  1.352        1.306   1.400 <.0001 1.235 1.202   1.268 <.0001 
Hispanic  1.056        0.996   1.119 0.0678 1.001 0.957   1.047 0.9715 
Native  1.336       1.151   1.551 0.0001 1.232 1.100   1.380 0.0003 
Other  0.337        0.159   0.714 0.0045 0.444 0.280   0.702 0.0005 
Marital        
Married (reference) 1.000      
Ever married  1.241       1.212   1.270 <.0001 1.495 1.472   1.518 <.0001 
Single  1.208        1.162   1.257 <.0001 1.405 1.367   1.445 <.0001 
Unknown 1.061 1.000   1.216 0.0496 1.309 1.257   1.364 <.0001 
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Table 18. The effect of histological and pathological factors on hazard ratio 
 Breast cancer specific survival Overall survival 
Factors Hazard Ratio 95% C.I. P-value Hazard Ratio 95% C.I. P-value 
 Cell differentiation grade       
Well (reference) 1.000   1.000   
Moderately  1.756       1.680   1.836 <.0001 1.185 1.137   1.234 <.0001 
Poorly differentiated 2.456       2.324   2.596 <.0001 1.513 1.403   1.632 <.0001 
Undifferentiated  2.287        2.108   2.482 <.0001 1.489 1.326   1.671 <.0001 
Unknown  1.608        1.469   1.760 <.0001 1.302 1.125   1.507 0.0004 
Tumor size       
2cm and less (reference) 1.000   1.000   
Paget’s disease 0.347 0.191   0.628 0.0005 2.046 1.988   2.254 0.0004 
2-5cm  1.734        1.688   1.781 <.0001 2.116 1.412   1.449 <.0001 
Over 5cm  1.745        1.666   1.828 <.0001 3.530 3.121   3.992 <.0001 
Unknown  1.178       1.077   1.289 0.0003 5.404 4.252   6.867 <.0001 
Lymph node       
Negative (reference) 1.000      
Positive  2.725        2.656   2.794 <.0001 1.751 1.715   1.788 <.0001 
Unknown  2.132       2.037   2.232 <.0001 2.160 2.082   2.224 <.0001 
Tumor Extension       
Localized (reference) 1.000      
Distant  4.294       4.082   4.517 <.0001 3.188 3.057   3.325 <.0001 
Regional  1.883        1.821   1.948 <.0001 1.580 1.540   1.622 <.0001 
Unclear  1.154        1.059   1.258 0.0011 1.005 0.937   1.078 0.8971 
Tumor Marker PRA       
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PRA positive (reference) 1.000      
Negative  1.257      1.228   1.287 <.0001 1.136 1.110   1.163 <.0001 
Borderline  1.304       1.197   1.421 <.0001 1.146 1.067   1.232 0.0002 
Unknown  1.018        0.963   1.075 0.5280 0.936 0.874   1.003 0.0624 
Tumor Marker ERA       
ERA positive (reference)       
Negative  1.363        1.330   1.397 <.0001 1.169 1.130   1.208 <.0001 
Borderline  1.298        1.180   1.427 <.0001 1.060 0.968   1.161 0.2082 
Unknown  1.216      1.149   1.285 <.0001 1.148 0.963   1.367 0.1227 
 
Table 19. The effect of treatments on hazard ratio 
 Breast cancer specific survival Overall survival 
Factors Hazard Ratio 95% C.I. P value Hazard Ratio 95% C.I. P value 
Surgery       
Surgery (reference) 1.000   1.000   
No surgery  2.165 2.108    2.223 <.0001 1.370 1.283   1.463 <.0001 
Unknown  2.229 1.977    2.513 <.0001 2.314 2.026   2.643 <.0001 
Radiation       
Radiation (reference) 1.000   1.000   
No radiation  1.296        1.244    1.349 <.0001 1.508 1.471   1.546 <.0001 
Unknown  1.039       0.981    1.101 0.1907 1.113 1.069   1.158 <.0001 
 
Table 18 showed that for breast cancer specific survival, the well differentiated tumor had a 
lower death hazard, and poorly differentiated tumor (2.456, P<0.0001) and undifferentiated tumor 
(2.287, P<0.0001) had higher mortality risk. Tumor size, lymph node metastasis status and tumor exten-
sion had significant effect on breast cancer survival.  The hazard ratio for comparing tumor size 2-5cm 
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and less than 2cm tumor was 1.734 (P<0.0001) and the hazard ratio of tumor size over 5cm group com-
pared to less than 2cm tumor group was 1.745 (P<0.0001). Positive lymph node metastasis had relative-
ly higher hazard (P<0.0001), the ratios were 2.725 for breast cancer specific survival and 1.751 for over-
all survival, respectively. Distant tumor extension had the highest risk for both breast cancer specific and 
overall survival (P<0.0001). The hazard ratios were 4.294 and 3.188, respectively. Patients with positive 
tumor maker (ERA or PRA) expression had better survival chance. Table 19 indicated that both surgery 
and radiotherapy were associated with lower mortality risk. For breast cancer specific survival, the haz-
ard ratio of non-surgery group compared to patients who received surgery treatment was 2.165 
(P<0.0001) and the hazard ratio between non-radiotherapy group and radiotherapy group was 1.296 
(P<0.0001). 
In summary, we found that after adjusted for the demographic factors, social factor and bio-
medical prognosis factors, the age of 20-39 year-old was a significant risk factor for breast cancer specif-
ic survival, and the 65 year-old and above age group had the worst overall survival chance. Among all 
race/ethnicity groups, the African Americans had the highest mortality risk (table 17) for breast cancer 
survival or overall survival. For both breast cancer specific survival and overall survival, larger tumor size, 
poorly differentiated tumor or undifferentiated tumor, lymph node and/or distant metastasis, and nega-
tive tumor markers associated with higher mortality risk. On the contrary, small tumor (less than 2cm), 
well differentiation tumor cell, no lymph node and/or distant organ metastasis, positive tumor markers 
and surgery or radiotherapy associated with less risk of death (tables 18 and 19).  
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3.4 Logistic regression analysis for 5-year survival status and the odds ratio  
In this part, a logistic regression analysis was used to seek the effects of demographic factors, 
social factor, histopathologic factors and clinical treatment factors on 5-year overall survival of patients 
and to calculate the odds ratio. In this section, a SAS logistic procedure was used to do regression analy-
sis (SAS institute inc. 2012). 
Table 20.  Relative odds ratio of demographic factors and social factor 
 Odds Ratio 95% confidence interval P-value 
age    
20-39   (reference) 1.000   
40 to 49                          1.234        1.176       1.295 <.0001 
50 to 64 0.968        1.334    1  0.916       1.022 0.2380 
65 and above 0.368 0.344       0.393 <.0001 
Race/ethnicity    
Non- Hispanic White (reference) 1.000   
Asian   1.298       1.168       1.441 <.   <.0001 
African American  0.723        0.691       0.757 <.0001 
Hispanic  1.031        0.956       1.111 0.4302 
Native  0.747        0.616       0.906       0.0031 
Other     4.949       2.046      10.556 0.0002 
Marital status    
Married (reference) 1.000   
Ever married  0.600      0.584       0.617 <.0001 
Single  0.667        0.636       0.700 <.0001 
Unknown 0.699 0.651       0.750 <.0001 
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Table 20 showed the results of logistic analysis for the 5-year survival status variable. After ad-
justed by all the other risk and prognosis factors, the odds ratio of over 65year-old group compared to 
20-39 year-old group was 0.368 (P<0.0001); the odds ratio of 40 to 49 years old group compared to 20-
39 year-old group was 1.234 (P<0.0001); the odds ratio of 50 to 64 years old group compared to 20-39 
year-old group was 0.968 (P=0.2380).  We concluded that the over 65 year-old age group had the lowest 
5 –year survival probability. African Americans had a lower 5-year survival chance, the odds ratio com-
pared to Non-Hispanic Whites was 0.723 (P<0.0001). Compared with married people, single (Odds Ratio 
0.667, P<0.0001) and currently single (Odds Ratio 0.600, P<0.0001) patients also had a lower 5-year sur-
vival chance. 
Table 21 showed that well differentiated tumor group had better 5-year relative survival proba-
bility (P<0.0001).  The odd ratios for poorly differentiated tumor group and undifferentiated tumor 
group were 0.573 and 0.585, respectively.  The odds ratio for the comparison between positive lymph 
node group and negative group was 0.446 (P<0.0001).  The odds ratios for regional and distant tumor 
extension were 0.464 and 0.144, respectively. All the results indicated that early disease stage (without 
lymph node metastasis or distant organ metastasis, smaller tumor size, localized tumor) had a better 5-
year survival chance.  The tumor marker ERA and PRA also affected survival: compared to positive ERA, 
the odds ratio of negative ERA was 0.646;   compare to positive PRA, the odds ratio of negative PRA was 
0.774.          
Table 22 showed that the clinical treatments (Surgery and/or Radiotherapy) had positive effect 
on the 5-year survival of breast cancer patients. Compared to the patients who received surgery treat-
ment, the odds ratio of the patients who did not receive any surgical treatment was 0.558 (P<0.0001) 
and also the radiotherapy had a positive effect on survival chance. Compared to radiotherapy group, the 
odds ratio of non-radiotherapy group was only 0.492 (P<0.0001).  
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 Table 21.  Relative odds ratio of histopathologic prognosis factors  
 Odds Ratio 95% confidence interval P-value 
Tumor cell differentiation grade    
Well differentiated (reference) 1.000   
Moderately      0.846       0.786       0.912 <.0001 
Poorly  0.573       0.499       0.658 <.0001 
Undifferentiated  0.585        0.473       0.724 <.0001 
Unknown  0.851        0.648       1.117 0.2441 
Tumor size    
2cm and less (reference) 1.000   
Paget disease 2.161 1.331      3.508 0.0018 
2 to 5cm  0.585       0.569       0.602 <.0001 
over 5cm  0.467        0.443       0.493 <.0001 
Unknown   0.868        0.788       0.955 0.0037 
Lymph node    
Negative (reference) 1.000   
Positive  0.446       0.436       0.456 <.0001 
Unknown   0.335        0.327       0.344 <.0001 
Tumor Marker ERA    
ERA positive (reference) 1.000   
Borderline  0.649        0.570       0.738 <.0001 
Negative  0.646        0.623       0.670 <.0001 
Unknown  0.692        0.608       0.788 <.0001 
Tumor Marker PRA    
PRA positive (reference) 1.000   
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Borderline  0.755        0.677       0.841 <.0001 
Negative  0.774        0.751       0.798 <.0001 
Unknown  1.038        0.962       1.120 0.3359 
Tumor extension    
Localized (reference) 1.000   
Distant  0.144        0.123       0.168 <.0001 
Regional  0.464        0.426       0.504 <.0001 
Unclear  0.753        0.602       0.941 0.0128 
 
Table 22.  Relative odds ratio of clinical treatments factors 
 Odds Ratio 95% confidence interval P-value 
Surgery    
Surgery treatment (reference) 1.000   
No surgery  0.558        0.489       0.635 <.0001 
Unknown     0.323        0.250       0.416 <.0001 
radiotherapy    
Radiotherapy (reference) 1.000   
No radiation  0.492       0.468       0.517 <.0001 
Unknown      0.951       0.884       1.024 0.1828 
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Table 23. The raw odds ratio and adjusted odds ratio for some risk and prognosis factors 
Factors Raw odds ratio and 95% C.I. adjusted odds ratio and 95% 
C.I. a 
adjusted odds ratio and 
95% C.I. b 
age    
20-39 0.728 (0.702    0.755)  0.750 (0.722     0.778) 0.951  (0.912   0.992) 
40-49 1.097 (1.067    1.127) 1.101 (1.071     1.132) 1.222  (1.185   1.261) 
Over 65 0.404 (0.396    0.412) 0.446 (0.437     0.454) 0.393  (0.384   0.402) 
Race/ethnicity    
Hispanic 1.001 (0.971   1.032) 0.858   (0.832    0.885) 0.957  (0.917   0.997) 
Black 0.570 (0.556   0.585) 0.545   (0.531    0.560) 0.709  (0.685   0.735) 
Asian 1.489 (1.436   1.545) 1.231   (1.186    1.278) 1.109  (1.054   1.167) 
Native 0.894 (0.797   1.003) 0.761   (0.676    0.856) 0.641  (0.546   0.752) 
Social factor  
married 1.742 (1.704   1.782) 1.642   (1.605    1.681) 1.274  (1.241   1.309) 
Ever married 0.742 (0.725   0.759) 0.920   (0.899    0.943) 0.811  (0.789   0.834) 
Cell grade  
Well  1.477 (1.435   1.521) 1.555   (1.509    1.602) 1.187  (1.149   1.226) 
poorly 0.516 (0.506   0.526) 0.454   (0.445    0.464) 0.661  (0.645   0.677) 
undifferentiated 0.528 (0.503   0.555) 0.450   (0.428    0.474) 0.659  (0.622   0.698) 
Tumor size  
2cm or less  1.320 (0.850   2.050) 1.108   (0.707    1.737) 0.488  (0.303   0.787) 
2-5 0.523 (0.336   0.812) 0.413   (0.264    0.648) 0.279  (0.173   0.450) 
Over 5cm 0.191 (0.123   0.297) 0.139   (0.089    0.218) 0.219  (0.136   0.353) 
Lymph node  
negative 3.470  (3.404  3.537) 3.799   (3.725    3.876) 2.249 (2.199   2.299) 
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Extension  
local 5.341  (5.139    5.550) 4.697   (4.512    4.891) 1.332 (1.262   1.405) 
Regional 1.265  (1.207    1.326) 1.205   (1.147    1.265) 0.639 (0.602   0.679) 
distant 0.298  (0.284    0.313) 0.237   (0.225    0.250) 0.201 (0.189   0.213) 
Tumor marker  
ERA positive 1.467  (1.430   1.504) 1.794   (1.747    1.843) 
 
1.538  (1.492  1.585) 
PRA negative 0.941  (0.860   1.029) 0.936   (0.854    1.027) 1.107  (0.919  1.125) 
PRA  positive 1.393  (1.273   1.524) 1.318   (1.201    1.446) 1.305  (1.179  1.145) 
Treatments  
Surgery 4.440  (3.770  5.229) 4.060   (3.431    4.804) 2.117  (1.909  2.349) 
Non surgery 0.447  (0.378  0.527) 0.434   (0.366    0.515) 0.391  (0.374  0.408) 
Radiotherapy 1.805  (1.774  1.836) 1.594   (1.566    1.622) 1.592  (1.561  1.624) 
Note: a adjusted by demographic factors and social factors; b adjusted by demographic factors, social factors and 
other prognosis factors. 
 
 
 From table 23 we found that after adjustment, the oldest age group patients still had a lower 
odds ratio (0.393), indicating a lower 5-year survival probability (P<0.0001).   African American also had 
the lowest odds ratio among all race/ethnicity groups (0.709, P<0.0001). This indicated that African 
American had lower 5-year relative survival chance. The subjects with well differentiated tumors, posi-
tive tumor markers, small tumor size or localized tumor had relatively higher odds ratios and better sur-
vival chance. Surgery and radiation treatments were all able to improve the 5-year survival chance. 
However, poorly differentiated or undifferentiated tumors, tumor size over 5cm and regional or distant 
extension had negative effects on breast cancer 5-year survival. Patients who did not receive any surgi-
cal treatments had lower 5-year survival chance (odds ratio 0.391). 
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4 RESEACH DEFICIENCY AND FURTHER PROSPECT 
In this study, some limitations must be considered. First of all, in this study, the majority of the 
participants were non-Hispanic White patients, and other race/ethnicity groups were less than 10%, re-
sulting in a significant effect on the p-value when we do survival analysis.  On the other hand, in breast 
cancer research, some other important risk factors should be considered, such as the patient’s personal 
history and patient’s social-economic status (SES). Postmenopausal age is considered as an important 
risk factor in breast cancer and highly associated with disease prognosis (Mandelblatt and Andrews 
1991). The preventable death rate was considered significantly higher in lower SES population because 
of less disease-related information they knew and less early detection and examination they received 
(Farley and Flannery, 1989). However, the SEER study program does not include such important infor-
mation. We expect in future study, the patients’ SES information, such as gross household income, edu-
cation level and the patients’ personal history to be included. Study containing some more factors will 
give us more accurate estimation of the prognosis and survival of breast cancer.  
5 CONCLUSIONS 
Despite some limitations, the results from this study provide evidence that many factors, such 
as demographic factors, social factors, and biomedical prognosis factors have significant effects on 
prognosis and survival of the female invasive breast cancer patients. The mortality increases in the older 
age groups. For example, postmenopausal females (over 50 year-old) have a higher risk of death. African 
American breast cancer patients have a higher mortality risk. Nodal involvement and distant metastasis, 
larger tumor size, negative tumor marker expression and tumor cell poorly differentiated or undifferen-
tiated are all significant high-risk biomedical factors. Besides, the lymph node and distant metastasis and 
larger tumor size are the symptoms of later disease stage. The patients in earlier disease stage and/or 
with smaller tumor size have lower risk of death. We can not control some risk factors or high-risk prog-
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nosis factors of breast cancer, such as the tumor cell differentiation grade and tumor markers. However, 
through early detection and valid treatments, such as surgery and radiotherapy, the risk of death can be 
effectively reduced. It was considered that the long-term survival of breast cancer patients was highly 
dependent on the stage of disease (National Cancer Institute 1990). Both Surgery and radiotherapy con-
tribute to the survival of breast cancer patients. Based on the evidence shown in this study, we conclude 
that early detection and treatment can prolong the lifespan of breast cancer patients and also improve 
their life quality. Furthermore, it is important for women to detect the breast cancer at an early stage, 
before it metastasizes to lymph nodes and distant organs.   
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APPENDICES 
SAS code: 
option nodate nocenter; 
libname seerbc 'D:\whw\data\seerbc'; 
libname format 'D:\whw\data\seerbc\format'; 
/*creast sas dataset*/ 
/*cases from San francisco, Connecticut, Metropolitan Detroit, Hawaii, Iowa, New Mexico,Seattle, Utah, Atlanta 
1973-2008*/ 
data seerbc.breast1; 
infile 'F:\thesis\thesis\thesis\SEER_1973_2008_TEXTDATA\incidence\yr1973_2008.seer9\breast.txt' lrecl=279; 
input @ 1   CASENUM  8.  /* Patient ID */ 
    @ 9   REG      10. /* SEER registry */ 
    @ 19  MAR_STAT 1.  /* Marital status at diagnosis */ 
    @ 20  RACE     2.  /* Race/ethnicityity */ 
    @ 22  ORIGIN   1.  /* Spanish surname or origin */ 
    @ 23  NHIA     1.  /* NHIA Derived Hisp Origin */ 
    @ 24  SEX      1.  /* Sex */ 
    @ 25  AGE_DX   3.  /* Age at diagnosis */ 
    @ 28  YR_BRTH  4.  /* Year of birth */ 
    @ 32  PLC_BRTH 3.  /* Place of birth */ 
    @ 35  SEQ_NUM  2.  /* Sequence number */ 
    @ 37  DATE_mo  2.  /* Month of diagnosis */ 
    @ 39  DATE_yr  4.  /* Year of diagnosis */ 
    @ 43  SITEO2V  $char4.  /* Primary site ICD-O-2 (1973+) */ 
    @ 47  LATERAL  1.  /* Laterality */ 
    @ 48  HISTO2V  4.  /* Histologic Type ICD-O-2 */ 
    @ 52  BEHO2V   1.  /* Behavior Code ICD-O-2 */ 
    @ 53  HISTO3V  4.  /* Histologic Type ICD-O-3 */ 
    @ 57  BEHO3V   1.  /* Behavior code ICD-O-3 */ 
    @ 58  GRADE    1.  /* Grade */ 
    @ 59  DX_CONF  1.  /* Diagnostic confirmation */ 
    @ 60  REPT_SRC 1.  /* Type of reporting source */ 
    @ 61  EOD10_SZ 3.  /* EOD 10 - size (1988+) */ 
    @ 64  EOD10_EX 2.  /* EOD 10 - extension */ 
    @ 66  EOD10_PE 2.  /* EOD 10 - path extension */ 
    @ 68  EOD10_ND 1.  /* EOD 10 - lymph node */ 
    @ 69  EOD10_PN 2.  /* EOD 10 - positive lymph nodes examined */ 
    @ 71  EOD10_NE 2.  /* EOD 10 - number of lymph nodes examined */ 
    @ 73  EOD13    $char13. /* EOD--old 13 digit */ 
    @ 86  EOD2     $char2.  /* EOD--old 2 digit */ 
    @ 88  EOD4     $char4.  /* EOD--old 4 digit */ 
    @ 92  EODCODE  $char1.  /* Coding system for EOD */ 
    @ 93  TUMOR_1V $char1.  /* Tumor marker 1 */ 
    @ 94  TUMOR_2V $char1.  /* Tumor marker 2 */ 
    @ 95  TUMOR_3V $char1.  /* Tumor marker 3 */ 
    @ 96  CS_SIZE  3.  /* CS Tumor size */ 
    @ 99  CS_EXT   3.  /* CS Extension */ 
    @ 102 CS_NODE  3.  /* CS Lymph Nodes */ 
    @ 105 CS_METS  2.  /* CS Mets at DX */ 
    @ 107 CS_SSF1  3.  /* CS Site-Specific Factor 1 */  
    @ 110 CS_SSF2  3.  /* CS Site-Specific Factor 2 */  
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    @ 113 CS_SSF3  3.  /* CS Site-Specific Factor 3 */  
    @ 116 CS_SSF4  3.  /* CS Site-Specific Factor 4 */  
    @ 119 CS_SSF5  3.  /* CS Site-Specific Factor 5 */  
    @ 122 CS_SSF6  3.  /* CS Site-Specific Factor 6 */  
    @ 125 CS_SSF25 3.  /* CS Site-Specific Factor 25 */      
    @ 128 D_AJCC_T 2.  /* Derived AJCC T */ 
    @ 130 D_AJCC_N 2.  /* Derived AJCC N */ 
    @ 132 D_AJCC_M 2.  /* Derived AJCC M */ 
    @ 134 D_AJCC_S 2.  /* Derived AJCC Stage Group */ 
    @ 136 D_SSG77  1.  /* Derived SS1977 */ 
    @ 137 D_SSG00  1.  /* Derived SS2000 */ 
    @ 138 D_AJCC_F 1.  /* Derived AJCC - flag */ 
    @ 139 D_SSG77F 1.  /* Derived SS1977 - flag */ 
    @ 140 D_SSG00F 1.  /* Derived SS2000 - flag */ 
    @ 141 CSV_ORG  6.  /* CS Version Input Original */ 
    @ 147 CSV_DER  6.  /* CS Version Derived */ 
    @ 153 CSV_CUR  6.  /* CS Version Input Current */ 
    @ 159 SURGPRIM 2.  /* RX Summ--surg prim site */ 
    @ 161 SCOPE    1.  /* RX Summ--scope reg LN sur */ 
    @ 162 SURGOTH  1.  /* RX Summ--surg oth reg/dis */ 
    @ 163 SURGNODE 2.  /* Number of lymph nodes */ 
    @ 165 RECONST  1.  /* Reconstruction */ 
    @ 166 NO_SURG  1.  /* Reason no cancer-directed surgery */ 
    @ 167 RADIATN  1.  /* Radiation */ 
    @ 168 RAD_BRN  1.  /* Radiation to Brain and/or CNS */ 
    @ 169 RAD_SURG 1.  /* Radiation sequence with surgery */ 
    @ 170 SS_SURG  2.  /* Site specific surgery (1983-1997) */ 
    @ 172 SRPRIM02 2.  /* Surgery to Primary Site */ 
    @ 174 SCOPE02  1.  /* Scope of lymph node surgery */ 
    @ 175 SRGOTH02 1.  /* Surgery to other sites */ 
    @ 176 REC_NO   2.  /* Record number */ 
    @ 178 O_SITAGE 1.  /* Age-site edit override */ 
    @ 179 O_SEQCON 1.  /* Sequence number-dx conf override */ 
    @ 180 O_SEQLAT 1.  /* Site-type-lat-seq override */ 
    @ 181 O_SURCON 1.  /* Surgery-diagnostic conf override */ 
    @ 182 O_SITTYP 1.  /* Site-type edit override */ 
    @ 183 H_BENIGN 1.  /* Histology edit override */ 
    @ 184 O_RPTSRC 1.  /* Report source sequence override */ 
    @ 185 O_DFSITE 1.  /* Seq-ill-defined site override */ 
    @ 186 O_LEUKDX 1.  /* Leuk-Lymph dx confirmation override */ 
    @ 187 O_SITBEH 1.  /* Site-behavior override */ 
    @ 188 O_EODDT  1.  /* Site-EOD-dx date override */ 
    @ 189 O_SITEOD 1.  /* Site-laterality-EOD override */ 
    @ 190 O_SITMOR 1.  /* Site-laterality-morph override */ 
    @ 191 TYPEFUP  1.  /* Type of followup expected */ 
    @ 192 AGE_REC  2.  /* Age recode */ 
    @ 194 SITE_REC 5.  /* Site recode */ 
    @ 199 SITE2_RE 5.  /* Site rec with Kaposis and mesothelioma */ 
    @ 204 ICDOTO9V $char4.  /* Recode ICD-O-2 to 9 */ 
    @ 208 ICDOT10V $char4.  /* Recode ICD-O-2 to 10 */ 
    @ 212 ICCCSITE $char3.  /* ICCC site recode */ 
    @ 215 ICCCSM   $char3.  /* SEER modified ICCC site recode */ 
    @ 218 ICCC3    $char3.  /* ICCC ICD-O-3 Recode */ 
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    @ 221 ICCC3EXT $char3.  /* ICCC ICD-O-3 Extended Recode */ 
    @ 224 BEHANAL  1.  /* Behavior recode for analysis */ 
    @ 225 ICD_CODE 1.  /* ICD-O Coding Scheme */ 
    @ 226 HISTREC  2.  /* Broad Histology recode */ 
    @ 228 BRAINREC 2.  /* Brain recode */ 
    @ 230 CS202SCH 3.  /* CS Schema v0202*/    
    @ 233 RAC_RECA 1.  /* Race recode A */ 
    @ 234 RAC_RECY 1.  /* Race recode Y */ 
    @ 235 NHIAREC  1.  /* Origin Recode NHIA */ 
    @ 236 HST_STGA 1.  /* SEER historic stage A */ 
    @ 237 AJCC_STG 2.  /* AJCC stage 3rd edition (1988+) */ 
    @ 239 AJ_3SEER 2.  /* SEER modified AJCC stage 3rd ed (1988+) */ 
    @ 241 SSG77    1.  /* SEER Summary Stage 1977 (1995-2000) */ 
    @ 242 SSG2000  1.  /* SEER Summary Stage 2000 2000 (2001-2003) */ 
    @ 243 NUMPRIMS 2.  /* Number of primaries */ 
    @ 245 FIRSTPRM 1.  /* First malignant primary indicator */ 
    @ 246 STCOUNTY 5.  /* State-county recode */ 
    @ 251 SURV_TM  4.  /* Survival time recode */ 
    @ 255 ICD_5DIG 5.  /* Cause of death to SEER site recode */ 
    @ 260 CODKM    5.  /* COD to site rec KM */ 
    @ 265 STAT_REC 1.  /* Vital status recode (study cutoff used) */ 
    @ 266 IHS      1.  /* IHS link */ 
    @ 267 hss_2000 1.  /* Historic SSG 2000 Stage */ 
    @ 268 AYA_rec  2.  /* AYA recode */ 
    @ 270 Lymphrec 2.  /* Lymphoma recode */ 
    @ 272 dth_cl   1.  /* SEER cause of death classification */ 
    @ 273 o_dth_cl 1.  /* SEER other cause of death classification */ 
    @ 274 exteval  1.  /* CS EXT/Size Eval */ 
    @ 275 nodeeval 1.  /* CS Nodes Eval */ 
    @ 276 metseval 1.  /* CS Mets Eval */      
    ; 
run; 
/*cases from Alaska, San Jose and Monterey, Los Angeles, Rural Georgia 1992-2008*/ 
data seerbc.breast2; 
infile 'F:\thesis\thesis\thesis\SEER_1973_2008_TEXTDATA\incidence\yr1992_2008.sj_la_rg_ak\breast.txt' 
lrecl=279; 
input @ 1   CASENUM  8.  /* Patient ID */ 
    @ 9   REG      10. /* SEER registry */ 
    @ 19  MAR_STAT 1.  /* Marital status at diagnosis */ 
    @ 20  RACE     2.  /* Race/ethnicityity */ 
    @ 22  ORIGIN   1.  /* Spanish surname or origin */ 
    @ 23  NHIA     1.  /* NHIA Derived Hisp Origin */ 
    @ 24  SEX      1.  /* Sex */ 
    @ 25  AGE_DX   3.  /* Age at diagnosis */ 
    @ 28  YR_BRTH  4.  /* Year of birth */ 
    @ 32  PLC_BRTH 3.  /* Place of birth */ 
    @ 35  SEQ_NUM  2.  /* Sequence number */ 
    @ 37  DATE_mo  2.  /* Month of diagnosis */ 
    @ 39  DATE_yr  4.  /* Year of diagnosis */ 
    @ 43  SITEO2V  $char4.  /* Primary site ICD-O-2 (1973+) */ 
    @ 47  LATERAL  1.  /* Laterality */ 
    @ 48  HISTO2V  4.  /* Histologic Type ICD-O-2 */ 
    @ 52  BEHO2V   1.  /* Behavior Code ICD-O-2 */ 
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    @ 53  HISTO3V  4.  /* Histologic Type ICD-O-3 */ 
    @ 57  BEHO3V   1.  /* Behavior code ICD-O-3 */ 
    @ 58  GRADE    1.  /* Grade */ 
    @ 59  DX_CONF  1.  /* Diagnostic confirmation */ 
    @ 60  REPT_SRC 1.  /* Type of reporting source */ 
    @ 61  EOD10_SZ 3.  /* EOD 10 - size (1988+) */ 
    @ 64  EOD10_EX 2.  /* EOD 10 - extension */ 
    @ 66  EOD10_PE 2.  /* EOD 10 - path extension */ 
    @ 68  EOD10_ND 1.  /* EOD 10 - lymph node */ 
    @ 69  EOD10_PN 2.  /* EOD 10 - positive lymph nodes examined */ 
    @ 71  EOD10_NE 2.  /* EOD 10 - number of lymph nodes examined */ 
    @ 73  EOD13    $char13. /* EOD--old 13 digit */ 
    @ 86  EOD2     $char2.  /* EOD--old 2 digit */ 
    @ 88  EOD4     $char4.  /* EOD--old 4 digit */ 
    @ 92  EODCODE  $char1.  /* Coding system for EOD */ 
    @ 93  TUMOR_1V $char1.  /* Tumor marker 1 */ 
    @ 94  TUMOR_2V $char1.  /* Tumor marker 2 */ 
    @ 95  TUMOR_3V $char1.  /* Tumor marker 3 */ 
    @ 96  CS_SIZE  3.  /* CS Tumor size */ 
    @ 99  CS_EXT   3.  /* CS Extension */ 
    @ 102 CS_NODE  3.  /* CS Lymph Nodes */ 
    @ 105 CS_METS  2.  /* CS Mets at DX */ 
    @ 107 CS_SSF1  3.  /* CS Site-Specific Factor 1 */  
    @ 110 CS_SSF2  3.  /* CS Site-Specific Factor 2 */  
    @ 113 CS_SSF3  3.  /* CS Site-Specific Factor 3 */  
    @ 116 CS_SSF4  3.  /* CS Site-Specific Factor 4 */  
    @ 119 CS_SSF5  3.  /* CS Site-Specific Factor 5 */  
    @ 122 CS_SSF6  3.  /* CS Site-Specific Factor 6 */  
    @ 125 CS_SSF25 3.  /* CS Site-Specific Factor 25 */      
    @ 128 D_AJCC_T 2.  /* Derived AJCC T */ 
    @ 130 D_AJCC_N 2.  /* Derived AJCC N */ 
    @ 132 D_AJCC_M 2.  /* Derived AJCC M */ 
    @ 134 D_AJCC_S 2.  /* Derived AJCC Stage Group */ 
    @ 136 D_SSG77  1.  /* Derived SS1977 */ 
    @ 137 D_SSG00  1.  /* Derived SS2000 */ 
    @ 138 D_AJCC_F 1.  /* Derived AJCC - flag */ 
    @ 139 D_SSG77F 1.  /* Derived SS1977 - flag */ 
    @ 140 D_SSG00F 1.  /* Derived SS2000 - flag */ 
    @ 141 CSV_ORG  6.  /* CS Version Input Original */ 
    @ 147 CSV_DER  6.  /* CS Version Derived */ 
    @ 153 CSV_CUR  6.  /* CS Version Input Current */ 
    @ 159 SURGPRIM 2.  /* RX Summ--surg prim site */ 
    @ 161 SCOPE    1.  /* RX Summ--scope reg LN sur */ 
    @ 162 SURGOTH  1.  /* RX Summ--surg oth reg/dis */ 
    @ 163 SURGNODE 2.  /* Number of lymph nodes */ 
    @ 165 RECONST  1.  /* Reconstruction */ 
    @ 166 NO_SURG  1.  /* Reason no cancer-directed surgery */ 
    @ 167 RADIATN  1.  /* Radiation */ 
    @ 168 RAD_BRN  1.  /* Radiation to Brain and/or CNS */ 
    @ 169 RAD_SURG 1.  /* Radiation sequence with surgery */ 
    @ 170 SS_SURG  2.  /* Site specific surgery (1983-1997) */ 
    @ 172 SRPRIM02 2.  /* Surgery to Primary Site */ 
    @ 174 SCOPE02  1.  /* Scope of lymph node surgery */ 
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    @ 175 SRGOTH02 1.  /* Surgery to other sites */ 
    @ 176 REC_NO   2.  /* Record number */ 
    @ 178 O_SITAGE 1.  /* Age-site edit override */ 
    @ 179 O_SEQCON 1.  /* Sequence number-dx conf override */ 
    @ 180 O_SEQLAT 1.  /* Site-type-lat-seq override */ 
    @ 181 O_SURCON 1.  /* Surgery-diagnostic conf override */ 
    @ 182 O_SITTYP 1.  /* Site-type edit override */ 
    @ 183 H_BENIGN 1.  /* Histology edit override */ 
    @ 184 O_RPTSRC 1.  /* Report source sequence override */ 
    @ 185 O_DFSITE 1.  /* Seq-ill-defined site override */ 
    @ 186 O_LEUKDX 1.  /* Leuk-Lymph dx confirmation override */ 
    @ 187 O_SITBEH 1.  /* Site-behavior override */ 
    @ 188 O_EODDT  1.  /* Site-EOD-dx date override */ 
    @ 189 O_SITEOD 1.  /* Site-laterality-EOD override */ 
    @ 190 O_SITMOR 1.  /* Site-laterality-morph override */ 
    @ 191 TYPEFUP  1.  /* Type of followup expected */ 
    @ 192 AGE_REC  2.  /* Age recode */ 
    @ 194 SITE_REC 5.  /* Site recode */ 
    @ 199 SITE2_RE 5.  /* Site rec with Kaposis and mesothelioma */ 
    @ 204 ICDOTO9V $char4.  /* Recode ICD-O-2 to 9 */ 
    @ 208 ICDOT10V $char4.  /* Recode ICD-O-2 to 10 */ 
    @ 212 ICCCSITE $char3.  /* ICCC site recode */ 
    @ 215 ICCCSM   $char3.  /* SEER modified ICCC site recode */ 
    @ 218 ICCC3    $char3.  /* ICCC ICD-O-3 Recode */ 
    @ 221 ICCC3EXT $char3.  /* ICCC ICD-O-3 Extended Recode */ 
    @ 224 BEHANAL  1.  /* Behavior recode for analysis */ 
    @ 225 ICD_CODE 1.  /* ICD-O Coding Scheme */ 
    @ 226 HISTREC  2.  /* Broad Histology recode */ 
    @ 228 BRAINREC 2.  /* Brain recode */ 
    @ 230 CS202SCH 3.  /* CS Schema v0202*/    
    @ 233 RAC_RECA 1.  /* Race recode A */ 
    @ 234 RAC_RECY 1.  /* Race recode Y */ 
    @ 235 NHIAREC  1.  /* Origin Recode NHIA */ 
    @ 236 HST_STGA 1.  /* SEER historic stage A */ 
    @ 237 AJCC_STG 2.  /* AJCC stage 3rd edition (1988+) */ 
    @ 239 AJ_3SEER 2.  /* SEER modified AJCC stage 3rd ed (1988+) */ 
    @ 241 SSG77    1.  /* SEER Summary Stage 1977 (1995-2000) */ 
    @ 242 SSG2000  1.  /* SEER Summary Stage 2000 2000 (2001-2003) */ 
    @ 243 NUMPRIMS 2.  /* Number of primaries */ 
    @ 245 FIRSTPRM 1.  /* First malignant primary indicator */ 
    @ 246 STCOUNTY 5.  /* State-county recode */ 
    @ 251 SURV_TM  4.  /* Survival time recode */ 
    @ 255 ICD_5DIG 5.  /* Cause of death to SEER site recode */ 
    @ 260 CODKM    5.  /* COD to site rec KM */ 
    @ 265 STAT_REC 1.  /* Vital status recode (study cutoff used) */ 
    @ 266 IHS      1.  /* IHS link */ 
    @ 267 hss_2000 1.  /* Historic SSG 2000 Stage */ 
    @ 268 AYA_rec  2.  /* AYA recode */ 
    @ 270 Lymphrec 2.  /* Lymphoma recode */ 
    @ 272 dth_cl   1.  /* SEER cause of death classification */ 
    @ 273 o_dth_cl 1.  /* SEER other cause of death classification */ 
    @ 274 exteval  1.  /* CS EXT/Size Eval */ 
    @ 275 nodeeval 1.  /* CS Nodes Eval */ 
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    @ 276 metseval 1.  /* CS Mets Eval */      
    ; 
run; 
/*cases from Great California, Kentucky, Louisana and New Jersey from 2000*/ 
data seerbc.breast3; 
infile 'F:\thesis\thesis\thesis\SEER_1973_2008_TEXTDATA\incidence\yr2000_2008.ca_ky_lo_nj\breast.txt' 
lrecl=279; 
input @ 1   CASENUM  8.  /* Patient ID */ 
    @ 9   REG      10. /* SEER registry */ 
    @ 19  MAR_STAT 1.  /* Marital status at diagnosis */ 
    @ 20  RACE     2.  /* Race/ethnicityity */ 
    @ 22  ORIGIN   1.  /* Spanish surname or origin */ 
    @ 23  NHIA     1.  /* NHIA Derived Hisp Origin */ 
    @ 24  SEX      1.  /* Sex */ 
    @ 25  AGE_DX   3.  /* Age at diagnosis */ 
    @ 28  YR_BRTH  4.  /* Year of birth */ 
    @ 32  PLC_BRTH 3.  /* Place of birth */ 
    @ 35  SEQ_NUM  2.  /* Sequence number */ 
    @ 37  DATE_mo  2.  /* Month of diagnosis */ 
    @ 39  DATE_yr  4.  /* Year of diagnosis */ 
    @ 43  SITEO2V  $char4.  /* Primary site ICD-O-2 (1973+) */ 
    @ 47  LATERAL  1.  /* Laterality */ 
    @ 48  HISTO2V  4.  /* Histologic Type ICD-O-2 */ 
    @ 52  BEHO2V   1.  /* Behavior Code ICD-O-2 */ 
    @ 53  HISTO3V  4.  /* Histologic Type ICD-O-3 */ 
    @ 57  BEHO3V   1.  /* Behavior code ICD-O-3 */ 
    @ 58  GRADE    1.  /* Grade */ 
    @ 59  DX_CONF  1.  /* Diagnostic confirmation */ 
    @ 60  REPT_SRC 1.  /* Type of reporting source */ 
    @ 61  EOD10_SZ 3.  /* EOD 10 - size (1988+) */ 
    @ 64  EOD10_EX 2.  /* EOD 10 - extension */ 
    @ 66  EOD10_PE 2.  /* EOD 10 - path extension */ 
    @ 68  EOD10_ND 1.  /* EOD 10 - lymph node */ 
    @ 69  EOD10_PN 2.  /* EOD 10 - positive lymph nodes examined */ 
    @ 71  EOD10_NE 2.  /* EOD 10 - number of lymph nodes examined */ 
    @ 73  EOD13    $char13. /* EOD--old 13 digit */ 
    @ 86  EOD2     $char2.  /* EOD--old 2 digit */ 
    @ 88  EOD4     $char4.  /* EOD--old 4 digit */ 
    @ 92  EODCODE  $char1.  /* Coding system for EOD */ 
    @ 93  TUMOR_1V $char1.  /* Tumor marker 1 */ 
    @ 94  TUMOR_2V $char1.  /* Tumor marker 2 */ 
    @ 95  TUMOR_3V $char1.  /* Tumor marker 3 */ 
    @ 96  CS_SIZE  3.  /* CS Tumor size */ 
    @ 99  CS_EXT   3.  /* CS Extension */ 
    @ 102 CS_NODE  3.  /* CS Lymph Nodes */ 
    @ 105 CS_METS  2.  /* CS Mets at DX */ 
    @ 107 CS_SSF1  3.  /* CS Site-Specific Factor 1 */  
    @ 110 CS_SSF2  3.  /* CS Site-Specific Factor 2 */  
    @ 113 CS_SSF3  3.  /* CS Site-Specific Factor 3 */  
    @ 116 CS_SSF4  3.  /* CS Site-Specific Factor 4 */  
    @ 119 CS_SSF5  3.  /* CS Site-Specific Factor 5 */  
    @ 122 CS_SSF6  3.  /* CS Site-Specific Factor 6 */  
    @ 125 CS_SSF25 3.  /* CS Site-Specific Factor 25 */      
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    @ 128 D_AJCC_T 2.  /* Derived AJCC T */ 
    @ 130 D_AJCC_N 2.  /* Derived AJCC N */ 
    @ 132 D_AJCC_M 2.  /* Derived AJCC M */ 
    @ 134 D_AJCC_S 2.  /* Derived AJCC Stage Group */ 
    @ 136 D_SSG77  1.  /* Derived SS1977 */ 
    @ 137 D_SSG00  1.  /* Derived SS2000 */ 
    @ 138 D_AJCC_F 1.  /* Derived AJCC - flag */ 
    @ 139 D_SSG77F 1.  /* Derived SS1977 - flag */ 
    @ 140 D_SSG00F 1.  /* Derived SS2000 - flag */ 
    @ 141 CSV_ORG  6.  /* CS Version Input Original */ 
    @ 147 CSV_DER  6.  /* CS Version Derived */ 
    @ 153 CSV_CUR  6.  /* CS Version Input Current */ 
    @ 159 SURGPRIM 2.  /* RX Summ--surg prim site */ 
    @ 161 SCOPE    1.  /* RX Summ--scope reg LN sur */ 
    @ 162 SURGOTH  1.  /* RX Summ--surg oth reg/dis */ 
    @ 163 SURGNODE 2.  /* Number of lymph nodes */ 
    @ 165 RECONST  1.  /* Reconstruction */ 
    @ 166 NO_SURG  1.  /* Reason no cancer-directed surgery */ 
    @ 167 RADIATN  1.  /* Radiation */ 
    @ 168 RAD_BRN  1.  /* Radiation to Brain and/or CNS */ 
    @ 169 RAD_SURG 1.  /* Radiation sequence with surgery */ 
    @ 170 SS_SURG  2.  /* Site specific surgery (1983-1997) */ 
    @ 172 SRPRIM02 2.  /* Surgery to Primary Site */ 
    @ 174 SCOPE02  1.  /* Scope of lymph node surgery */ 
    @ 175 SRGOTH02 1.  /* Surgery to other sites */ 
    @ 176 REC_NO   2.  /* Record number */ 
    @ 178 O_SITAGE 1.  /* Age-site edit override */ 
    @ 179 O_SEQCON 1.  /* Sequence number-dx conf override */ 
    @ 180 O_SEQLAT 1.  /* Site-type-lat-seq override */ 
    @ 181 O_SURCON 1.  /* Surgery-diagnostic conf override */ 
    @ 182 O_SITTYP 1.  /* Site-type edit override */ 
    @ 183 H_BENIGN 1.  /* Histology edit override */ 
    @ 184 O_RPTSRC 1.  /* Report source sequence override */ 
    @ 185 O_DFSITE 1.  /* Seq-ill-defined site override */ 
    @ 186 O_LEUKDX 1.  /* Leuk-Lymph dx confirmation override */ 
    @ 187 O_SITBEH 1.  /* Site-behavior override */ 
    @ 188 O_EODDT  1.  /* Site-EOD-dx date override */ 
    @ 189 O_SITEOD 1.  /* Site-laterality-EOD override */ 
    @ 190 O_SITMOR 1.  /* Site-laterality-morph override */ 
    @ 191 TYPEFUP  1.  /* Type of followup expected */ 
    @ 192 AGE_REC  2.  /* Age recode */ 
    @ 194 SITE_REC 5.  /* Site recode */ 
    @ 199 SITE2_RE 5.  /* Site rec with Kaposis and mesothelioma */ 
    @ 204 ICDOTO9V $char4.  /* Recode ICD-O-2 to 9 */ 
    @ 208 ICDOT10V $char4.  /* Recode ICD-O-2 to 10 */ 
    @ 212 ICCCSITE $char3.  /* ICCC site recode */ 
    @ 215 ICCCSM   $char3.  /* SEER modified ICCC site recode */ 
    @ 218 ICCC3    $char3.  /* ICCC ICD-O-3 Recode */ 
    @ 221 ICCC3EXT $char3.  /* ICCC ICD-O-3 Extended Recode */ 
    @ 224 BEHANAL  1.  /* Behavior recode for analysis */ 
    @ 225 ICD_CODE 1.  /* ICD-O Coding Scheme */ 
    @ 226 HISTREC  2.  /* Broad Histology recode */ 
    @ 228 BRAINREC 2.  /* Brain recode */ 
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    @ 230 CS202SCH 3.  /* CS Schema v0202*/    
    @ 233 RAC_RECA 1.  /* Race recode A */ 
    @ 234 RAC_RECY 1.  /* Race recode Y */ 
    @ 235 NHIAREC  1.  /* Origin Recode NHIA */ 
    @ 236 HST_STGA 1.  /* SEER historic stage A */ 
    @ 237 AJCC_STG 2.  /* AJCC stage 3rd edition (1988+) */ 
    @ 239 AJ_3SEER 2.  /* SEER modified AJCC stage 3rd ed (1988+) */ 
    @ 241 SSG77    1.  /* SEER Summary Stage 1977 (1995-2000) */ 
    @ 242 SSG2000  1.  /* SEER Summary Stage 2000 2000 (2001-2003) */ 
    @ 243 NUMPRIMS 2.  /* Number of primaries */ 
    @ 245 FIRSTPRM 1.  /* First malignant primary indicator */ 
    @ 246 STCOUNTY 5.  /* State-county recode */ 
    @ 251 SURV_TM  4.  /* Survival time recode */ 
    @ 255 ICD_5DIG 5.  /* Cause of death to SEER site recode */ 
    @ 260 CODKM    5.  /* COD to site rec KM */ 
    @ 265 STAT_REC 1.  /* Vital status recode (study cutoff used) */ 
    @ 266 IHS      1.  /* IHS link */ 
    @ 267 hss_2000 1.  /* Historic SSG 2000 Stage */ 
    @ 268 AYA_rec  2.  /* AYA recode */ 
    @ 270 Lymphrec 2.  /* Lymphoma recode */ 
    @ 272 dth_cl   1.  /* SEER cause of death classification */ 
    @ 273 o_dth_cl 1.  /* SEER other cause of death classification */ 
    @ 274 exteval  1.  /* CS EXT/Size Eval */ 
    @ 275 nodeeval 1.  /* CS Nodes Eval */ 
    @ 276 metseval 1.  /* CS Mets Eval */      
    ; 
run; 
proc sort data=seerbc.breast1; by CASENUM;run; 
proc sort data=seerbc.breast2; by CASENUM;run;  
proc sort data=seerbc.breast3; by CASENUM;run; 
data seerbc.breast; 
merge seerbc.breast1 seerbc.breast2 seerbc.breast3;  
by CASENUM; 
run; 
data seerbc.total; 
merge seerbc.breast seerbc.time_month;  
by CASENUM; 
run; 
DATA seerbc.one; set seerbc.total; 
keep CASENUM REG MAR_STAT SEX AGE_DX YR_BRTH SEQ_NUM DATE_mo DATE_yr SITEO2V LATERAL HISTO3V 
BEHO3V GRADE DX_CONF REPT_SRC EOD10_SZ EOD10_EX EOD10_ND EOD10_PN EOD10_NE TUMOR_1V TU-
MOR_2V SURGPRIM NO_SURG RADIATN RAD_SURG SS_SURG TYPEFUP SITE_REC BEHANAL HISTREC AGE_REC 
RAC_RECY NHIAREC HST_STGA AJCC_STG AJ_3SEER SSG77 SSG2000 NUMPRIMS FIRSTPRM ICD_5DIG STAT_REC 
dth_cl o_dth_cl time_mon; 
if sex=1 then delete; 
if  BEHO3V=3; 
if 1990<=DATE_yr<=2002; 
if GRADE in (5,6,7,8) then delete; 
if HST_STGA=0 then delete; 
if ssg77=0 | ssg2000=0 then delete; 
if AJCC_STG=0 then delete; 
if REPT_SRC in (6,7,8) then delete; 
if AGE_DX=999 then delete; 
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if AGE_DX<20 then delete; 
if TYPEFUP in (1,3) then delete; 
if rac_recy=9 then delete; 
if HISTO3V>=8800 then delete; 
run; 
/*categories*/ 
data seerbc.categ;set seerbc.one; 
racegroup=0; 
if RAC_RECY=1 & NHIAREC=0 then racegroup=1; 
if RAC_RECY=2 & NHIAREC=0 then racegroup=2; 
if NHIAREC=1 then racegroup=3; 
if RAC_RECY=4 & NHIAREC=0 then racegroup=4; 
if RAC_RECY=3 & NHIAREC=0 then racegroup=5; 
if RAC_RECY=7 & NHIAREC=0 then racegroup=6; 
if RAC_RECY=9 & NHIAREC=0 then racegroup=6; 
agegroup=0; 
if AGE_DX<040 then agegroup=1; 
if 040<=AGE_DX<050 then agegroup=2; 
if 050<=AGE_DX<065 then agegroup=3; 
if 065<=AGE_DX then agegroup=4; 
marital=0; 
if MAR_STAT=2 then marital=1; 
if MAR_STAT in (3,4,5) then marital=2; 
if MAR_STAT=1 then marital=3; 
if MAR_STAT=9 then marital=4; 
cellgrade=0; 
if GRADE=1 then cellgrade=1; 
if GRADE=2 then cellgrade=2; 
if GRADE=3 then cellgrade=3; 
if GRADE=4 then cellgrade=4; 
if GRADE=9 then cellgrade=5; 
tumorsize=0; 
if EOD10_SZ<=020 then tumorsize=1; 
if 020<EOD10_SZ<=050 then tumorsize=2; 
if 990=>EOD10_SZ>050 | EOD10_SZ=998 then tumorsize=3; 
if EOD10_SZ=997 then tumorsize=4; 
if EOD10_SZ=999then tumorsize=5; 
extension=0; 
if EOD10_EX in (05,10) then extension=1; 
else if 10<=EOD10_EX<20 then extension=1; 
else if 20<=EOD10_EX<70 then extension=2; 
else if 70<=EOD10_EX<99 then extension=3; 
else if EOD10_EX=99 then extension=4; 
lymphnode=0; 
if EOD10_PN=00 & EOD10_ND=0 then lymphnode=1; 
if EOD10_ND in (1,2,3,4,5,6,7,8) | 01<=EOD10_PN<=89 then lymphnode=2; 
if EOD10_ND in (1,2,3,4,5,6,7,8) | EOD10_PN in (90, 95, 97) then lymphnode=2; 
if EOD10_ND=0 & EOD10_PN in (98,99) then lymphnode=3; 
if EOD10_ND=9 & EOD10_PN in (0,98,99) then lymphnode=3; 
surgery=0; 
if SURGPRIM=00 | SS_SURG in (00,01,02,03,04,05,06,07)then surgery=1; 
if SURGPRIM=99 | SS_SURG=09 then surgery=3; 
if SURGPRIM=. & SS_SURG=98 then surgery=2; 
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if 10<=SURGPRIM<99 then surgery=2; 
if 10<=SS_SURG<=90 then surgery=2; 
radiation=0; 
if RADIATN in (0,7) then radiation=1; 
if RADIATN in (1,2,3,4,5,6) then radiation=2; 
if RADIATN in (8,9) then radiation=3; 
ERA=0; 
if TUMOR_1V=1 then ERA=1; 
if TUMOR_1V=2 then ERA=2; 
if TUMOR_1V=3 then ERA=3; 
if TUMOR_1V in (0,8,9) then ERA=4; 
PRA=0; 
if TUMOR_2V=1 then PRA=1; 
if TUMOR_2V=2 then PRA=2; 
if TUMOR_2V=3 then PRA=3; 
if TUMOR_2V in (0,8,9) then PRA=4; 
cause=0; 
if ICD_5DIG=26000 then cause=1; 
else if ICD_5DIG in (41000, 99999) then cause=4; 
else if 20000<ICD_5DIG<26000 | 26000<ICD_5DIG<38000 then cause=2; 
else if 38000<=ICD_5DIG<=50300 then cause=3; 
else if ICD_5DIG=0 then cause=5; 
run; 
proc format library=format; 
value dth_cl 
0='alive or dead of other cause' 
1='dead' 
9='unknown'; 
value cellgrade 
1='well differentiated' 
2='moderately differentiated' 
3='poorly differentiated' 
4='undifferentiated' 
5='unknown'; 
value agegroup 
1='20-39' 
2='40 to 49' 
3='50 to 64' 
4='65 and above'; 
value racegroup 
1='non-hispanic white' 
2='black' 
3='hispanic' 
4='asian' 
5='native' 
6='other'; 
value marital 
1='married' 
3='single' 
2='ever married' 
4='unknown'; 
value tumorsize 
1='2cm or less' 
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2='2 to 5cm' 
3='over 5cm' 
4='Paget' 
5='unknown'; 
value extension 
1='localized' 
2='regional' 
3='distant' 
4='unclear'; 
value lymphnode 
1='negative' 
2='positive' 
3='unknown'; 
value surgery 
1='no surgery' 
2='surgery' 
3='unknown'; 
value radiation 
1='no radiation' 
2='radiation' 
3='unknown'; 
value ERA 
1='positive' 
2='negative' 
3='borderline' 
4='unknown'; 
value PRA 
1='positive' 
2='negative' 
3='borderline' 
4='unknown'; 
value cause 
1='Breast cancer ' 
2='Other cancer' 
3='Non_cancer death' 
4='unclear' 
5='alive'; 
run; 
libname format 'D:\whw\data\seerbc\format'; 
options fmtsearch=(format); 
/*frequency tables*/ 
proc freq data=seerbc.categ; 
table racegroup agegroup marital cellgrade tumorsize extension lymphnode surgery radiation era pra cause 
racegroup*marital agegroup*dth_cl agegroup*cause racegroup*cause racegroup*dth_cl cellgrade*extension sur-
gery*radiation/chisq; 
format racegroup racegroup. agegroup agegroup. marital marital. cellgrade cellgrade. tumorsize tumorsize.  
extension extension. lymphnode lymphnode. surgery surgery. radiation radiation. era era. pra pra.  
cause cause. dth_cl dth_cl. ; 
run; 
/*mean and median age*/ 
proc means data=seerbc.categ  mean median; 
var age_dx; 
title 'median age at diagnosis'; 
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run; 
/*age groups and survival status two-way table*/ 
proc template; 
define crosstabs Base.Freq.CrossTabFreqs; 
define header myheader; 
text 'age/survival or death status Two-Way Table'; 
title 'age groups and survival status two-way table'; 
end; 
end; 
run; 
ods listing close; 
ods html file='body.html'; 
proc freq data=seerbc.categ; 
tables agegroup*cause/chisq; 
format agegroup agegroup. cause cause.; 
run; 
ods html close; 
ods listing; 
 
/*race and survival or death status*/ 
proc template; 
define crosstabs Base.Freq.CrossTabFreqs; 
define header myheader; 
text 'Race/ethnicity and survival or death status two-way table'; 
title 'Race/ethnicity and survival or death status two-way table'; 
end; 
end; 
run; 
ods listing close; 
ods html file='body.html'; 
proc freq data=seerbc.categ; 
tables racegroup*cause/chisq; 
format cause cause. racegroup racegroup.; 
run; 
ods html close; 
ods listing; 
 
/*race and marital status*/ 
proc template; 
define crosstabs Base.Freq.CrossTabFreqs; 
define header myheader; 
text 'race/marital status Two-Way Table'; 
title 'Race_Ethnic and Marital Status'; 
end; 
end; 
run; 
ods listing close; 
ods html file='body.html'; 
proc freq data=seerbc.categ; 
tables racegroup*marital/chisq; 
format racegroup racegroup. marital marital.; 
run; 
ods html close; 
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ods listing; 
 
/*tumor cell diffrrenciation grade and tumor extension*/ 
proc template; 
define crosstabs Base.Freq.CrossTabFreqs; 
define header myheader; 
text 'cell diffrrenciation grade and tumor extension Two-Way Table'; 
title 'cell diffrrenciation grade and tumor extension'; 
end; 
end; 
run; 
ods listing close; 
ods html file='body.html'; 
proc freq data=seerbc.categ; 
tables cellgrade*extension/chisq; 
format cellgrade cellgrade. extension extension.; 
run; 
ods html close; 
ods listing; 
 
/*treatment*/ 
proc template; 
define crosstabs Base.Freq.CrossTabFreqs; 
define header myheader; 
text 'Surgery and Radiotherapy Two-Way Table'; 
title 'Summary of Treatments'; 
end; 
end; 
run; 
ods listing close; 
ods html file='body.html'; 
proc freq data=seerbc.categ; 
tables surgery*radiation/chisq; 
format surgery surgery. radiation radiation.; 
run; 
ods html close; 
ods listing; 
/*add censoring indicator for breast cancer specific survival analysis*/ 
data seerbc.life;  
set seerbc.categ; 
censor=0; 
if cause in (2,3,4,5) then censor=1; 
run; 
/*create dummy variable*/ 
data seerbc.life1; 
set seerbc.life; 
age20_39=0;  
if agegroup=1 then age20_39=1; 
age40_49=0; 
if agegroup=2 then age40_49=1; 
age50_64=0; 
if agegroup=3 then age50_64=1; 
over65=0; 
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if agegroup=4 then over65=1; 
White=0; 
if racegroup=1 then White=1; 
Black=0; 
if racegroup=2 then Black=1; 
Hispanic=0; 
if racegroup=3 then Hispanic=1; 
Asian=0; 
if racegroup=4 then Asian=1; 
Native=0; 
if racegroup=5 then Native=1; 
Other=0; 
if racegroup=6 then Other=1; 
married=0; 
if marital=1 then married=1; 
ever_married=0; 
if marital=2 then ever_married=1; 
single=0; 
if marital=3 then single=1; 
mar_unknown=0; 
if marital=4 then mar_unknown=1; 
well=0; 
if cellgrade=1 then well=1; 
morderately=0; 
if cellgrade=2 then morderately=1; 
poorly=0; 
if cellgrade=3 then poorly=1; 
undiff=0; 
if cellgrade=4 then undiff=1; 
grade_unknown=0; 
if cellgrade=5 then grade_unknown=1; 
less2=0; 
if tumorsize=1 then less2=1; 
size2to5=0; 
if tumorsize=2 then size2to5=1; 
size5=0; 
if tumorsize=3 then size5=1; 
paget=0; 
if tumorsize=4 then paget=1; 
size_unknown=0; 
if tumorsize=5 then size_unknown=1; 
local=0; 
if extension=1 then local=1; 
regional=0; 
if extension=2 then regional=1; 
distant=0; 
if extension=3 then distant=1; 
ext_unknown=0; 
if extension=4 then ext_unknown=1; 
lnnegative=0; 
if lymphnode=1 then lnnegative=1; 
lnpositive=0; 
if lymphnode=2 then lnpositive=1; 
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ln_unknown=0; 
if lymphnode=3 then ln_unknown=1; 
no_surgery=0; 
if surgery=1 then no_surgery=1; 
surg=0; 
if surgery=2 then surg=1; 
surg_unknown=0; 
if surgery=3 then surg_unknown=1; 
no_rad=0; 
if radiation=1 then no_rad=1; 
rad=0; 
if radiation=2 then rad=1; 
rad_unknown=0; 
if radiation=3 then rad_unknown=1; 
e_positive=0; 
if ERA=1 then e_positive=1; 
e_negative=0; 
if ERA=2 then e_negative=1; 
e_border=0; 
if ERA=3 then e_border=1; 
e_unknown=0; 
if ERA=4 then e_unknown=1; 
p_positive=0; 
if PRA=1 then p_positive=1; 
p_negative=0; 
if PRA=2 then p_negative=1; 
p_border=0; 
if PRA=3 then p_border=1; 
p_unknown=0; 
if PRA=4 then p_unknown=1; 
run; 
/*add censoring indicator for overall survival analysis*/ 
data seerbc.life2; 
set seerbc.life1; 
censor1=0; 
if cause=5 then censor1=1; 
run; 
/*effect of factors on survival and hazard function*/ 
/*age*/ 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life1 alpha=0.05  ALPHAQT=0.05 method=life intervals=(0 to 150 by 3)  plots=( 
s(pvalue),ls, lls, h, p); 
title 'effect of age on breast cancer specific survival or hazard function'; 
time time_mon*censor(1); 
test White Black Hispanic Asian Native Other married ever_married single mar_unknown well morderately poorly 
undiff grade_unknown less2 size2to5 size5 paget size_unknown local regional distant ext_unknown lnpositive 
lnnegative ln_unknown no_surgery surg surg_unknown no_rad rad rad_unknown e_positive e_negative e_border 
e_unknown p_positive p_negative p_border p_unknown; 
strata agegroup/test= WILCOXON LOGRANK  adjust=sidak diff=control('65 and above'); 
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format  agegroup agegroup.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life2 alpha=0.05  ALPHAQT=0.05 method=life intervals=(0 to 150 by 3)  plots=( 
s(pvalue),ls, lls, h, p) notable; 
title 'effect of age on overall survival or hazard function'; 
time time_mon*censor1(1); 
test White Black Hispanic Asian Native Other married ever_married single mar_unknown  
well morderately poorly undiff grade_unknown less2 size2to5 size5 size_unknown local regional distant 
ext_unknown  
lnpositive lnnegative ln_unknown no_surgery surg surg_unknown no_rad rad rad_unknown e_positive e_negative 
e_border 
e_unknown p_positive p_negative p_border p_unknown; 
strata agegroup/test= WILCOXON LOGRANK  adjust=sidak diff=control('65 and above'); 
format  agegroup agegroup.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*Race_Ethnic*/ 
title 'effect of Race/ethnicity on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p)  ; 
time time_mon*censor(1); 
test agegroup marital cellgrade tumorsize extension lymphnode surgery radiation era pra; 
strata racegroup/test= WILCOXON LOGRANK  ; 
format  racegroup racegroup.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*Marital Status*/ 
title 'effect of Marital Status on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
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ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=marital 
outtest=marital_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup cellgrade tumorsize extension lymphnode surgery radiation era pra; 
strata marital/ test= WILCOXON LOGRANK  ; 
format  marital marital.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*cellgrade*/ 
title 'effect of tumor cell differentiation grade on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=cellgrade 
outtest=cellgrade_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital tumorsize extension lymphnode surgery radiation era pra; 
strata cellgrade/test= WILCOXON LOGRANK  ; 
format  cellgrade cellgrade.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*tumorsize*/ 
title 'effect of tumorsize at diagnosis on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=tumorsize 
outtest=tumorsize_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade extension lymphnode surgery radiation era pra; 
strata tumorsize/test= WILCOXON LOGRANK  ; 
format  tumorsize tumorsize.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*extension*/ 
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title 'effect of tumor extension on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=extension 
outtest=extension_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade tumorsize lymphnode surgery radiation era pra; 
strata extension/test= WILCOXON LOGRANK  ; 
format extension extension.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*lymphnode*/ 
title 'effect of lymph node metastais on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) 
outsurv=lymphnode outtest=lymphnode_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup cellgrade marital tumorsize extension surgery radiation era pra; 
strata lymphnode/test= WILCOXON LOGRANK  ; 
format lymphnode lymphnode.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*ERA*/ 
title 'effect of tumor marker ERA on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=ERA 
outtest=ERA_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade tumorsize extension lymphnode surgery radiation pra; 
strata ERA/test= WILCOXON LOGRANK  ; 
format ERA ERA.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
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ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*PRA*/ 
title 'effect of tumor marker PRA on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 180 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=PRA 
outtest=PRA_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup cellgrade marital tumorsize extension lymphnode surgery radiation era; 
strata PRA/test= WILCOXON LOGRANK  ; 
format PRA PRA.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*surgery*/ 
title 'effect of surgery treatment on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 150 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=surgery 
outtest=surgery_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade tumorsize extension lymphnode radiation ERA PRA; 
strata surgery/test= WILCOXON LOGRANK  ; 
format surgery surgery.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*radiation*/ 
title 'effect of radiotherapy on breast cancer specific survival or hazard function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 150 by 3) plots=( s(pvalue),ls, lls, h, p) 
outsurv=radiotherapy outtest=radiotherapy_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade tumorsize extension lymphnode surgery era pra; 
strata radiation/test= WILCOXON LOGRANK  ; 
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format radiation radiation.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*combined treatments*/ 
title 'effect of treatment on breast cancer specific survival function'; 
ODS HTML; 
ODS GRAPHICS ON; 
ODS TRACE ON;   
ODS OUTPUT WilUniChiSq =_wilcox1 
LogUniChiSq =_logrank1; 
proc lifetest data=seerbc.life method=life intervals=(0 to 150 by 3) plots=( s(pvalue),ls, lls, h, p) outsurv=treatment 
outtest=treatment_statitic  ; 
time time_mon*censor(1); 
test agegroup racegroup marital cellgrade tumorsize extension lymphnode era pra; 
strata radiation surgery/test= WILCOXON LOGRANK  ; 
format radiation radiation. surgery surgery.; 
run; 
ODS OUTPUT CLOSE; 
ODS TRACE OFF; 
ODS HTML CLOSE; 
ODS GRAPHICS OFF; 
 
/*Cox proportional hazard regression*/ 
/*Cox proportional hazard regression for bc specific survival */ 
ods graphics on; 
proc phreg data=seerbc.life plots=(survival cumhaz); 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated')  
tumorsize(ref='2cm or less') lymphnode(ref='negative') surgery(ref='surgery') radiation(ref='radiation') extension 
(ref='localized') ERA (ref='positive') PRA (ref='positive') /param=ref; 
model time_mon*censor(1)=racegroup agegroup marital  cellgrade tumorsize lymphnode  extension ERA PRA sur-
gery radiation grade_size age_ext age_grade race_treat surg_rad grade_ext grade_ln size_ln surg_ext rad_grade  
race_mar surg_size ERA_PRA marker_surg surg_grade marker_rad surg_ln_size/rl selection=stepwise ties=efron; 
age_ext=agegroup*extension; 
age_grade=agegroup*cellgrade; 
surg_grade=surgery*cellgrade; 
surg_size=surgery*tumorsize; 
race_mar=racegroup*marital; 
rad_grade=radiation*cellgrade; 
surg_ext=surgery*extension; 
size_ln=tumorsize*lymphnode; 
grade_ln=cellgrade*lymphnode; 
grade_ext=cellgrade*extension; 
surg_rad=surgery*radiation; 
race_treat=racegroup*surgery*radiation; 
grade_size=cellgrade*tumorsize; 
surg_ln_size=surgery*lymphnode*tumorsize; 
ERA_PRA=ERA*PRA; 
marker_surg=ERA*PRA*surgery; 
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marker_rad=ERA*PRA*radiation; 
baseline  survival=_all_ CUMHAZ=_all_; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation. extension extension. ERA ERA. PRA PRA.; 
run; 
ods graphics off; 
 
ods graphics on; 
proc phreg data=seerbc.life plots=(survival cumhaz); 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated')  
tumorsize(ref='2cm or less') lymphnode(ref='negative') surgery(ref='surgery') radiation(ref='radiation') extension 
(ref='localized') ERA (ref='positive') PRA (ref='positive') /param=ref; 
model time_mon*censor(1)=racegroup agegroup marital surg_size cellgrade tumorsize lymphnode  extension  ERA 
PRA surgery radiation race_treat grade_ext size_ln rad_grade age_ext race_mar marker_surg  marker_rad/rl 
ties=efron; 
age_ext=agegroup*extension; 
race_mar=racegroup*marital; 
rad_grade=radiation*cellgrade; 
size_ln=tumorsize*lymphnode; 
grade_ext=cellgrade*extension; 
race_treat=racegroup*surgery*radiation; 
marker_surg=ERA*PRA*surgery; 
marker_rad=ERA*PRA*radiation; 
surg_size=surgery*tumorsize; 
baseline  survival=_all_ CUMHAZ=_all_; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation. extension extension. ERA ERA. PRA PRA.; 
run; 
ods graphics off; 
 
/*Cox proportional hazard regression for overall survival */ 
ods graphics on; 
proc phreg data=seerbc.life2 plots=(survival cumhaz); 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated')tumorsize(ref='2cm or less') lymphnode(ref='negative') surgery(ref='surgery') 
radiaion(ref='radiation') extension (ref='localized') ERA (ref='positive') PRA (ref='positive') /param=ref; 
model time_mon*censor1(1)=racegroup agegroup marital  cellgrade tumorsize lymphnode  extension ERA PRA 
surgery radiation grade_size race_age surg_rad grade_ext grade_ln size_ln surg_ext rad_grade race_mar surg_size 
ERA_PRA marker_surg surg_grade marker_rad surg_ln_size/rl selection=stepwise ties=efron; 
surg_grade=surgery*cellgrade; 
surg_size=surgery*tumorsize; 
race_mar=racegroup*marital; 
rad_grade=radiation*cellgrade; 
surg_ext=surgery*extension; 
size_ln=tumorsize*lymphnode; 
grade_ln=cellgrade*lymphnode; 
grade_ext=cellgrade*extension; 
surg_rad=surgery*radiation; 
race_age=racegroup*agegroup; 
grade_size=cellgrade*tumorsize; 
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surg_ln_size=surgery*lymphnode*tumorsize; 
ERA_PRA=ERA*PRA; 
marker_surg=ERA*PRA*surgery; 
marker_rad=ERA*PRA*radiation; 
baseline  survival=_all_ CUMHAZ=_all_; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation. extension extension. ERA ERA. PRA PRA.; 
run; 
ods graphics off; 
 
ods graphics on; 
proc phreg data=seerbc.life2 plots=(survival cumhaz); 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated')  
tumorsize(ref='2cm or less') lymphnode(ref='negative') surgery(ref='surgery') radiation(ref='radiation') extension 
(ref='localized') ERA (ref='positive') PRA (ref='positive') /param=ref; 
model time_mon*censor1(1)=racegroup agegroup marital  cellgrade tumorsize lymphnode  extension ERA PRA 
surgery radiation  race_age  grade_ext grade_ln size_ln rad_grade race_mar surg_size ERA_PRA marker_surg 
surg_grade marker_rad surg_ln_size/rl  ties=efron; 
surg_grade=surgery*cellgrade; 
surg_size=surgery*tumorsize; 
race_mar=racegroup*marital; 
rad_grade=radiation*cellgrade; 
size_ln=tumorsize*lymphnode; 
grade_ln=cellgrade*lymphnode; 
grade_ext=cellgrade*extension; 
race_age=racegroup*agegroup; 
surg_ln_size=surgery*lymphnode*tumorsize; 
ERA_PRA=ERA*PRA; 
marker_surg=ERA*PRA*surgery; 
marker_rad=ERA*PRA*radiation; 
baseline  survival=_all_ CUMHAZ=_all_; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation. extension extension. ERA ERA. PRA PRA.; 
run; 
ods graphics off; 
 
/*censoring indicator for 5-year relative survival*/ 
data seerbc.logit; 
set seerbc.life2; 
five=0; 
if time_mon>=60 then five=1; 
surv=1; 
if five=0 & cause in (1,2,3,4) then surv=0; 
grade_size=cellgrade*tumorsize;  
race_treat=radiation*surgery*race;  
age_ext=agegroup*extension;  
surg_rad=surgery*radiation;  
grade_ext=cellgrade*extension;  
grade_ln=cellgrade*lymphnode;  
size_ln=tumorsize* lymphnode; 
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surg_ext =surgery*extension; 
rad_grade=radiation*grade;  
race_mar=race*marital;  
surg_size=surgery*tumorsize;  
ERA_PRA=ERA*PRA;  
marker_surg=surgery*ERA*PRA;  
surg_grade=surgery*cellgrade;  
marker_rad=radiation*ERA*PRA;  
surg_ln_size=surgery*lymphnode*tumorsize; 
run; 
proc format library=format; 
value five 
0='less than 5 years' 
1='5 years and above'; 
value surv 
0='death' 
1='5 year survival'; 
run; 
 
/*full logstic model*/ 
proc logistic data=seerbc.logit; 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated') tumorsize(ref='2cm or less ') lymphnode(ref='negative') extension (ref='localized') sur-
gery(ref='surgery') radiation(ref='radiation') ERA(ref='positive') PRA(ref='positive')/param=ref ; 
model fiveyr_surv(event='survival or censor')=racegroup agegroup marital  cellgrade tumorsize lymphnode  exten-
sion ERA PRA surgery radiation grade_size race_treat age_ext surg_rad grade_ext grade_ln size_ln surg_ext 
rad_grade race_mar surg_size ERA_PRA marker_surg surg_grade marker_rad surg_ln_size /selection=stepwise 
risklimits; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation.  extension extension. ERA ERA. PRA PRA. survival survival. 
bcscensor bcscensor. fiveyr fiveyr. fiveyr_surv fiveyr_surv.; 
run; 
 
 
proc logistic data=seerbc.logit; 
class racegroup(ref='non-hispanic white') agegroup(ref='20-39') marital(ref='married') cellgrade(ref='well 
differentiated')tumorsize(ref='2cm or less ') lymphnode(ref='negative') extension (ref='localized') sur-
gery(ref='surgery') radiation(ref='radiation')ERA(ref='positive') PRA(ref='positive')/param=ref ; 
model fiveyr_surv(event='survival or censor')=racegroup agegroup marital  cellgrade tumorsize lymphnode  exten-
sion ERA PRA surgery radiation grade_size race_treat age_ext grade_ext surg_ext rad_grade surg_grade 
race_mar marker_surg surg_grade marker_rad/risklimits; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation.  extension extension. ERA ERA. PRA PRA. survival survival. 
bcscensor bcscensor. fiveyr fiveyr. fiveyr_surv fiveyr_surv.; 
run; 
 
/*dummy variable model selection*/ 
data one;set seerbc.logit; 
/*interactions*/ 
/*age*ext*/ 
Local_20_39=local*age20_39; local_40_49=local*age40_49; local_50_64=local*age50_64; local_65=local*over65; 
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reg_20_39=regional*age20_39;reg_40_49=regional*age40_49;reg_50_64=regional*age50_64;reg_65=regional*ov
er65;dist_20_39=distant*age20_39;dist_40_49=distant*age40_49;dist_50_64=distant*age50_64;dist_65=distant*
over65;unext_20_39=ext_unknown*age20_39;unext_40_49=ext_unknown*age40_49;unext_50_64=ext_unknown
*age50_64;unext_65=ext_unknown*over65; 
/*cellgrade*extension*/ 
well_local=well*local;mod_local=moderately*local;poor_local=poorly*local;undiff_local=undiff*local;unknown_lo
cal=grade_unknown*local; 
well_region=well*regional;mod_region=moderately*regional;poor_region=poorly*regional;undiff_region=undiff*r
egional;unknown_region=grade_unknown*regional; 
well_dist=well*distant;mod_dist=moderately*distant;poor_dist=poorly*distant;undiff_dist=undiff*distant;unknow
n_dist=grade_unknown*distant; 
well_unknown=well*ext_unknown;mod_unknown=moderately*ext_unknown;poor_unknown=poorly*ext_unkno
wn;undiff_unknown=undiff*ext_unknown;grad_ext_unknown=grade_unknown*ext_unknown; 
/*size*lymphnode*/ 
less2_lnpo=less2*lnpositive;size2to5_lnpo=size2to5*lnpositive;size5_lnpo=size5*lnpositive;paget_lnpo=paget*lnp
ositive;unknownsz_lnpo=size_unknown*lnpositive; 
less2_lnne=less2*lnnegative;size2to5_lnne=size2to5*lnnegative;size5_lnne=size5*lnnegative;paget_lnne=paget*l
nnegative;unknownsz_lnne=size_unknown*lnnegative; 
less2_lnno=less2*ln_unknown;size2to5_lnno=size2to5*ln_unknown;size5_lnno=size5*ln_unknown;paget_lnno=p
aget*ln_unknown;unknownsz_lnno=size_unknown*ln_unknown; 
/*cellgrade*size*/ 
well_less2=well*less2;mod_less2=moderately*less2;poor_less2=poorly*less2;undiff_less2=undiff*less2;unknown_
less2=grade_unknown*less2; 
well_sz2_5=well*size2to5;mod_sz2_5=moderately*size2to5;poor_sz2_5=poorly*size2to5;undiff_sz2_5=undiff*siz
e2to5;unknown_sz2_5=grade_unknown*size2to5; 
well_sz5=well*size5;mod_sz5=moderately*size5;poor_sz5=poorly*size5;undiff_sz5=undiff*size5;unknown_sz5=gr
ade_unknown*size5; 
well_unsz=well*size_unknown;mod_unsz=moderately*size_unknown;poor_unsz=poorly*size_unknown;undiff_un
sz=undiff*size_unknown;unknown_unsz=grade_unknown*size_unknown; 
/*cellgrade*lymphnode*/ 
well_lnpo=well*lnpositive;mod_lnpo=moderately*lnpositive;poor_lnpo=poorly*lnpositive;undiff_lnpo=undiff*lnp
ositive;unknown_lnpo=grade_unknown*lnpositive; 
well_lnno=well*ln_unknown;mod_lnno=moderately*ln_unknown;poor_lnno=poorly*ln_unknown;undiff_lnno=un
diff*ln_unknown;unknown_lnno=grade_unknown*ln_unknown; 
well_lnne=well*lnnegative;mod_lnne=moderately*lnnegative;poor_lnne=poorly*lnnegative;undiff_lnne=undiff*ln
negative;unknown_lnne=grade_unknown*lnnegative; 
/*surgery*radiotherapy*/ 
sur_rad=surg*rad;nosur_rad=no_surgery*rad;unsur_rad=surg_unknown*rad; 
sur_norad=surg*no_rad;nosur_norad=no_surgery*no_rad;unsur_norad=surg_unknown*no_rad; 
sur_unrad=surg*rad_unknown;nosur_unrad=no_surgery*rad_unknown;unsur_unrad=surg_unknown*rad_unkno
wn; 
/*cellgrade*radiation*/ 
well_rad=well*rad;modrad=moderately*rad;poorrad=poorly*rad;undiffrad=undiff*rad;unknownrad=grade_unkno
wn*rad; 
well_norad=well*no_rad;mod_norad=moderately*no_rad;poor_norad=poorly*no_rad;undiff_norad=undiff*no_ra
d;unknown_norad=grade_unknown*no_rad; 
well_unrad=well*rad_unknown;mod_unrad=moderately*rad_unknown;poor_unrad=poorly*rad_unknown;undiff_
unrad=undiff*rad_unknown;unknown_unrad=grade_unknown*rad_unknown; 
/*tumorsize*surgery*/ 
less2_surg=less2*surg;size2to5_surg=size2to5*surg;size5_surg=size5*surg;paget_surg=paget*surg;unknownsz_sur
g=size_unknown*surg; 
less2_nosurg=less2*no_surgery;size2to5_nosurg=size2to5*no_surgery;size5_nosurg=size5*no_surgery;paget_nos
urg=paget*no_surgery;unknownsz_nosurg=size_unknown*no_surgery; 
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less2_unsurg=less2*surg_unknown;size2to5_unsurg=size2to5*surg_unknown;size5_unsurg=size5*surg_unknown;
paget_unsurg=paget*surg_unknown;unknownsz_unsurg=size_unknown*surg_unknown; 
/*surgery*extension*/ 
sur_local=surg*local;nosur_local=no_surgery*local;unsur_local=surg_unknown*local; 
sur_region=surg*regional;nosur_region=no_surgery*regional;unsur_region=surg_unknown*regional; 
sur_dist=surg*distant;nosur_dist=no_surgery*distant;unsur_dist=surg_unknown*distant; 
sur_unkn=surg*ext_unknown;nosur_unkn=no_surgery*ext_unknown;unsur_unkn=surg_unknown*ext_unknown; 
/*radiation*extension*/ 
lo-
cal_rad=local*rad;region_rad=regional*rad;dist_rad=distant*rad;unext_rad=ext_unknown*rad;local_norad=local*
no_rad;region_norad=regional*no_rad;dist_norad=distant*no_rad;unext_norad=ext_unknown*no_rad;local_unra
d=local*rad_unknown;region_unrad=regional*rad_unknown;dist_unrad=distant*rad_unknown;unext_unrad=ext_
unknown*rad_unknown; 
/*ERA*PRA*/ 
ep_pp=e_positive*p_positive;ep_pn=e_positive*p_negative;ep_pb=e_positive*p_border;ep_pu=e_positive*p_un
known; 
en_pp=e_negative*p_positive;en_pn=e_negative*p_negative;en_pb=e_negative*p_border;en_pu=e_negative*p_
unknown; 
eb_pp=e_border*p_positive;eb_pn=e_border*p_negative;eb_pb=e_border*p_border;eb_pu=e_border*p_unkno
wn; 
eu_pp=e_unknown*p_positive;eu_pn=e_unknown*p_negative;eu_pb=e_unknown*p_border;eu_pu=e_unknown*
p_unknown; 
run; 
/*dummy var model */ 
proc logistic data=one; 
model fiveyr_surv(event='survival or censor')=age20_39 age40_49 age50_64 over65 White Black Hispanic Asian 
Native Other married ever_married single mar_unknown well moderately poorly undiff grade_unknown less2 
size2to5 size5 paget size_unknown local regional distant ext_unknown lnnegative lnpositive ln_unknown 
no_surgery surg surg_unknown no_rad rad rad_unknown e_positive e_negative e_border e_unknown p_positive 
p_negative p_border p_unknown local_20_39 local_40_49 local_50_64 local_65 reg_20_39 reg_40_49 reg_50_64 
reg_65 dist_20_39 dist_40_49 dist_50_64 dist_65 unext_20_39 unext_40_49 unext_50_64 unext_65 well_local 
mod_local poor_local undiff_local unknown_local well_region mod_region poor_region undiff_region un-
known_region well_dist mod_dist poor_dist undiff_dist unknown_dist well_unknown mod_unknown 
poor_unknown undiff_unknown grad_ext_unknown less2_lnpo size2to5_lnpo size5_lnpo paget_lnpo 
unknownsz_lnpo less2_lnne size2to5_lnne size5_lnne paget_lnne unknownsz_lnne less2_lnno size2to5_lnno 
size5_lnno paget_lnno unknownsz_lnno well_less2 mod_less2 poor_less2 undiff_less2 unknown_less2 well_sz2_5 
mod_sz2_5 poor_sz2_5 undiff_sz2_5 unknown_sz2_5 well_sz5 mod_sz5 poor_sz5 undiff_sz5 unknown_sz5 
well_unsz mod_unsz poor_unsz undiff_unsz unknown_unsz well_lnpo mod_lnpo poor_lnpo undiff_lnpo un-
known_lnpo well_lnno mod_lnno poor_lnno undiff_lnno unknown_lnno well_lnne mod_lnne poor_lnne 
undiff_lnne unknown_lnne sur_rad nosur_rad unsur_rad sur_norad nosur_norad unsur_norad sur_unrad 
nosur_unrad unsur_unrad well_rad modrad poorrad undiffrad unknownrad well_norad mod_norad poor_norad 
undiff_norad unknown_norad well_unrad mod_unrad poor_unrad undiff_unrad unknown_unrad less2_surg 
size2to5_surg size5_surg paget_surg unknownsz_surg less2_nosurg size2to5_nosurg size5_nosurg paget_nosurg 
unknownsz_nosurg less2_unsurg size2to5_unsurg size5_unsurg paget_unsurg unknownsz_unsurg sur_local 
nosur_local unsur_local sur_region nosur_region unsur_region sur_dist nosur_dist unsur_dist sur_unkn 
nosur_unkn unsur_unkn local_rad region_rad dist_rad unext_rad local_norad region_norad dist_norad 
unext_norad local_unrad region_unrad dist_unrad unext_unrad ep_pp ep_pn ep_pb ep_pu en_pp en_pn en_pb 
en_pu eb_pp eb_pn eb_pb eb_pu eu_pp eu_pn eu_pb eu_pu/risklimits SELECTION=stepwise ; 
format  
racegroup racegroup. agegroup agegroup. Marital marital. cellgrade cellgrade. tumorsize tumorsize. lymphnode 
lymphnode. surgery surgery. radiation radiation. extension extension. ERA ERA. PRA PRA. survival survival. 
fiveyr_surv fiveyr_surv.; 
run; 
